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ABSTRACT 
Ineffective reversal of neuromuscular blockade is a prevalent issue for patients recovering from 
anesthesia, impacting over a third of our perioperative patient populations. This issue imposes 
the risk of postoperative complications for perioperative patients that can lead to prolonged 
operating room stay, prolonged recovery room stay, unplanned re-intubations, and unwarranted 
intensive care admissions. There is a new reversal agent, sugamamdex, which is revolutionizing 
how anesthesia providers are reversing neuromuscular blockade, in that it provides more timely 
and effective reversal. Sugammadex has recently been approved by the Food and Drug 
Administration (FDA), many hospitals remain reluctant to have it available on their hospital 
formulary. The main purpose of this Doctor of Nursing Practice (DNP) project was to develop an 
evidence-based clinical practice guideline (CPG) for the regulated use of sugammadex as an 
alternative reversal agent, to be used by anesthesia providers at a hospital in the Phoenix area. 
The objective is to motivate implementation of evidence-based recommendations for 
sugammadex by providing a high quality guideline to key leaders of the organization to promote 
and implement change. The Knowledge to Action Framework was utilized as the quality 
improvement, conceptual framework to encourage translation of current evidence into best 
practices. Expert practitioners (N=4) utilized the Appraisal of Guidelines for Research & 
Evaluation II (AGREE II) as an assessment tool to determine the quality and applicability of the 
developed CPG. The CPG’s overall assessment achieved a score of 96%, leading to each 
appraiser recommending its use without modifications. Results were disseminated to key 
anesthesia leaders who presented the guidelines to the pharmacy and therapeutics committee 
which resulted in the addition of sugammadex for use by anesthesia. 
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INTRODUCTION 
The Centers for Disease Control and Prevention (CDC), through the National Hospital 
Discharge Survey, estimated that there are 51.4 million surgeries performed in the United States 
(US) every year (Brull & Kopman, 2017). If one conservatively estimates that 60% of these 
surgical procedures required general anesthesia with muscle relaxation, it would equate out to 
30.8 million patients that receive neuromuscular blocking agents (NMBA) annually (Brull & 
Kopman, 2017). This is significant due to the incidence of residual blockade, which has been 
found to occur in 41% of patients that receive muscle relaxation (Naguib, Kopman, & Ensor, 
2007). Residual blockade causes patients to have postoperative weakness, which leads to poor 
respiratory mechanics, loss of airway protective reflexes, and increase risk of complications. It is 
conservatively estimated that one-third of all surgical patients will experience some degree of 
postoperative weakness, which would result in 10.1 million patients experiencing prolonged 
paralysis and an increased risk of postoperative complications annually in the US (Brull & 
Kopman, 2017). Further, 0.8% of all surgical patients will have a serious postoperative 
respiratory complication amounting to 81,417 patients every year in the US (Brull & Kopman, 
2017). This has led to an increased emphasis on measures to enhance both effective monitoring 
and reversal of neuromuscular blockade. One way to address this issue is through the 
development of a clinical practice guideline (CPG), which includes evidence based research to 
guide practice.  
CPGs provide recommendations driven by published research. This minimizes ineffective 
patient care, and reduces the variety of care from different healthcare organizations (Tymkow, 
2011). There has been an extensive push for healthcare professionals to attain new knowledge 
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and adapt their clinical care to current best practices, which is known as evidence-based practice 
(EBP). EBP intertwines the currently best available research in the literature with clinical 
expertise to result in enhanced patient care (Zaccagnini & White, 2011). The DNP prepared 
advanced practice nurse (APRN) has many roles, including identifying gaps in knowledge and 
propel the implementation of EBP in all aspects of healthcare, such as the incorporation of CPGs 
into practice. There is a current EBP lag in healthcare organizations related to the fear of change 
to ‘how it has always been done’ or the status quo, which can lead to inappropriate patient care. 
The transition of information into policies has been found to have a lag time of eight to fifteen 
years, which highlights the need for enhanced provider education and guidelines that evolve with 
research (Dobbins, Ciliska, Estabrooks, & Hayward, 2005). This ineffective evolution of best-
practice is only found to be more astonishing when it takes numerous years for the development 
of CPGs from current literature recommendations. DNP providers can promote best practice by 
ensuring that CPGs are developed from evidence-based recommendations and continually evolve 
with the current literature.  
Background Knowledge 
Ineffective reversal of neuromuscular blockade may lead to prolonged paralysis and 
weakness of surgical patients whom have been administered NMBAs. This is known as 
postoperative residual curarization (PORC), which can lead to respiratory insufficiency, 
hypoxemia, and even death if unnoticed. PORC has become a highly prevalent issue in our 
healthcare organizations for surgical patients recovering from anesthesia whom received NMBA 
intraoperatively by decreasing surgical patients’ ability to protect their own airway and ventilate 
adequately. This becomes a serious consideration for providers in the US due to the majority of 
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cases, up to 60%, are being performed as outpatient, single-day cases, in which patients are being 
sent home with NMBAs still affecting their neuromuscular junctions (Farhan, Moreno-Duarte, 
McLean, & Eikermann, 2014). Effective muscle relaxation is a critical component of providing 
exceptional anesthesia for tracheal intubation and maintaining surgical exposure, however it does 
require a delicate balance due to the potential for inadequate recovery from anesthesia and 
recurarization. Anesthesia providers employ just enough medication to adequately anesthetize 
and paralyze (render immobile) intraoperative patients for surgical procedures, while 
maintaining the capability of patients to safely and rapidly recover from anesthesia at the end of 
the case.  
The prevalence of recurarization in the postoperative phase has been reported by 
numerous meta-analyses to be anywhere from 38 to 41% of surgical patients (Farhan et al., 2014; 
Naguib, Kopman, & Esnor, 2007). Approximately 30% of all patients that received a NMBA 
throughout the intraoperative phase show clinical signs of impaired function of the pharyngeal 
and esophageal muscles which are used as protective mechanisms for the airway (Robertis et al., 
2016). It is also alarming that not all patients will show obvert clinical signs of recurarization 
until respiratory distress and hypoxemia. Farhan et al. (2014) found that PORC increased the risk 
of respiratory adverse events, postoperative weakness, prolonged recovery, and increased 
postoperative care unit (PACU) stay. The authors defined a respiratory adverse event as either 
impaired hypoxic ventilatory drive, impaired respiratory muscle function, impaired protection of 
airway from aspiration, or critical situation that required supplemental oxygen to maintain 
saturations greater than 90%. Due to the associated, potentially fatal adverse events, adequate 
reversal from neuromuscular blockade is a clinically serious problem. Specific patient identifiers 
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associated with an increased risk of complications related to the use of NMBAs are elderly 
patients; morbidly obese patients; patients presenting with preexisting neurological, 
neuromuscular, respiratory, cardiac, renal, and liver disease; and patients with contraindications 
to currently used reversal agents (Carron, Baratto, Zarantonello, & Ori, 2016). Complications 
secondary to PORC can be costly for our healthcare organizations, in which the cost of managing 
postoperative patients with respiratory complications was nearly $63,000 compared to only 
$5,000 for uncomplicated cases per patient (Farhan et al., 2014). 
Another concern related to undesired paralysis is during a rapid sequence induction with 
rocuronium, a non-depolarizing NMBA, to control the patient’s airway with the inability to 
intubate. This method of anesthesia care is used to protect an airway for patients that are 
considered high risk for aspiration. This is a common practice for patients that are obese, 
pregnant, have delayed gastric emptying, have active gastrointestinal reflux, or requiring 
emergent surgery and have not fasted prior to surgery. The most commonly used NMBA for 
rapid sequence cases is succinylcholine because of its short duration of action of 5-10 minutes, 
however there are many situations the contraindicate its use. Contraindications to the use of 
succinylcholine include pediatric males; history of malignant hyperthermia, atypical 
pseudocholinesterase, or muscular dystrophies; recent stroke, burn, or musculocutaneous 
injuries; and chronic renal failure with hyperkalemia (Naguib, 2015). The only other NMBA for 
these cases is rocuronium, which has a duration of 35 minutes for normal, healthy patients. As a 
result, to its longer duration of action, there is the warranted concern of a cannot ventilate-cannot 
intubate (CVCI) event (refer to ‘definitions of terms’ section for clarity of CVCI event). This can 
lead to respiratory failure and cardiac arrest without the employment of emergency respiratory 
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strategies. Current NMBA reversal practices are simply not timely enough for these rare events, 
however there is a new reversal breakthrough that has been found to be effective and promising.  
Current Reversal Practices and CPGs 
Currently the universal practice of reversing patients’ neuromuscular blockade is with the 
use of neostigmine. Neostigmine is an acetylcholinesterase inhibitor that does not directly affect 
the NMBA, but only indirectly increases acetylcholine in the neuromuscular junction to increase 
competition for nicotinic receptor sites (Naguib, 2015). There are many side effects with the use 
of acetylcholinesterase inhibitors that necessitates the addition of an anticholinergic drug to 
offset these symptoms. Common symptoms include bradycardia, bronchospasm, and other 
muscarinic side effects that are undesirable for surgical patients recovering from anesthesia (Liu, 
et al., 2017). The addition of an anticholinergic drug, such as glycopyrrolate matched with 
neostigmine, is associated with its own unwarranted side effects, such as tachycardia and dry 
mouth (Naguib, 2015). Further, neostigmine is unable to reverse deep neuromuscular blockade, 
as assessed be a train-of-four (TOF) count less than two, which requires delayed recovery and 
increased hospital costs (Kopman & Eikermann, 2009) (refer to ‘definitions of terms’ section for 
clarity of TOF). It is also alarming that even with a TOF count of four, which is the maximum 
twitch count, there is the possibility of 70% blockade of nicotinic receptors which still 
predisposes the patient to PORC (Liu, et al., 2017).  
Recent Reversal Breakthrough 
The US Food and Drug Administration has recently approved a new reversal agent, 
sugammadex, which is revolutionizing how practitioners treat neuromuscular blockade in 
surgical patients. Sugammadex was originally approved in the European Union in 2008 and has 
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made significant advancement in the management reversing neuromuscular blockade (Keating, 
2016). It has been approved in numerous countries around the world, but has only recently been 
approved in the US. Sugammadex’s mechanism is completely different compared to 
acetylcholinesterase inhibitors, in that it directly affects the NMBAs that were administered 
intraoperatively. Sugammadex reverses neuromuscular blockade by encapsulating and 
inactivating aminosteroid NMBAs by creating a 1:1, inactive complex. Further, there is a 
negative gradient that is formed that causes more aminosteroid NMBAs to diffuse away from the 
neuromuscular junction (Naguib, 2015). The end result of sugammadex is a reduced amount of 
free NMBA that is able to block nicotinic receptor sites in the neuromuscular junction, thus 
causing a reversal of neuromuscular blockade (Keating, 2016). Sugammadex is biologically 
inactive molecule that has very few side effects and is excreted in the urine unchanged (Naguib, 
2015). One limiting factor is that sugammadex only reverses steroidal-induced neuromuscular 
blockade, as seen with rocuronium and vecuronium; it is unable to reverse cistracurium or 
atracurium-induced neuromuscular blockade related to its chemical structure (Naguib, 2015). 
The use of sugammadex has also been attributed to allergic reactions, which is an undesirable 
reaction of the immune system to a drug or allergen, similarly to how NMBAs have been 
attributed with allergic reactions. Obviously, it is pertinent that anesthesia personnel are always 
prepared to treat allergic reactions or anaphylaxis for all perioperative patients. Sugammadex has 
been attributed to a full reversal from neuromuscular blockade in only three minutes after 
administration, which is far lower than neostigmine’s 10 to 30-minute onset of action (Chambers 
et al., 2010; Lexicomp, 2017; Keating, 2016). This makes the addition of sugammadex into 
anesthesia practice highly advantagous for prevention of potential CVCI catastrophic outcomes. 
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The speed of reversal associated with sugammadex has the capability of drastically reducing the 
risk of morbidity and mortality in a CVCI events after rocuronium induced neuromuscular 
blockade (Chambers et al, 2010).  
Definitions of Terms 
Postoperative Residual Recurarization (PORC) 
PORC is the persistent residual paralysis after the administration of a NMBA following 
recovery of anesthesia (Farhan et al., 2014). PORC is clinically defined as a TOF ratio of less 
than 0.9 (Carron, Zarantonello, Tellaroli, & Ori, 2016).  
Train-of-Four Monitoring (TOF) 
TOF monitoring is typically used to assess the depth of neuromuscular transmission when 
NMBA are administered to block musculoskeletal activity. The TOF ratio is the comparison of 
the fourth twitch to the first twitch to evaluate the degree of weakness, and is able to estimate the 
percentage of neuromuscular blockade from 70 to 100% (Nagelhout, 2016). It has been well 
established that recovery from neuromuscular blockade can be monitored with a TOF ratio 
greater than 0.9 (Robertis, et al., 2016). Acceleromyography provides objective monitoring of 
the TOF ration and is considered the gold standard, however it is rarely employed (Carron et al., 
2016).  
Rapid Sequence Induction 
Rapid sequence inductions are employed when patients are considered to be at risk for 
aspiration of gastrointestinal contents, which is associated with various sequela. It involves rapid 
intravenous administration of an anesthetic and paralytic without bag mask ventilation prior to 
direct laryngoscopy and tracheal intubation. This technique prevents insufflation of the stomach 
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and minimizes intra-abdominal pressure fluctuations that leads to vomiting and aspiration. 
Patients at risk for aspiration include active comorbidities of obesity, pregnancy, gastrointestinal 
reflux, bowel obstruction, and other causes of full stomach. Rapid sequence inductions are 
associated with a wide range of potentially dangerous adverse events and death (Carron et al., 
2016). Currently the only NMBAs with a rapid enough onset of action are succinylcholine and 
rocuronium. In patient scenarios that prevent the use of succinylcholine, it is recommended to 
have sugammadex available to potentially reverse the longer duration of rocuronium (Chambers 
et al., 2010). 
Cannot Ventilate – Cannot Intubate (CVCI) 
CVCI events are related to the provider’s inability to either intubate the trachea or 
ventilate with bag-mask ventilation (Carron et al., 2016). When longer duration NMBAs are used 
for muscle relaxation the patient is unable to resume spontaneous ventilation or maintain a patent 
airway, and the risks of complications are highly increased.  
Local Problem 
This DNP project was designed for the development of a CPG for a healthcare 
organization that has been resistant to the incorporation of sugammadex into the practice setting. 
The designated facility currently does not employ the use of sugammadex for fear of increased 
costs and perception that it is not clinically needed. The institution is currently considering the 
addition of sugammadex to the pharmacy’s formulary but does not have a current protocol or 
guideline for appropriate reversal measures. The development of a facility focused CPG would 
include evidence-based recommendations on appropriate clinical scenarios and patient 
populations in which sugammadex would be a highly appropriate measure.  
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Associated Comorbidities 
As noted previously, there are many comorbidities that have been associated with PORC 
and increased postoperative complications, such as obesity, obstructive sleep apnea, and chronic 
respiratory diseases. Obesity has been a highly prevalent issue in the US affecting 37% of the 
adult population and 17% of the pediatric population (Ogden, Carroll, Fryar, & Flegal, 2015). 
Obstructive sleep apnea has been diagnosed for more than 18 million people in the US; as well 
there is a high correlation with obesity, in which the estimated rate of undiagnosed sleep apnea is 
80 to 95% of obese, perioperative patients (Nagelhout, 2014). The CDC found that 12.8 million 
or 5.2% of US adults have been diagnosed with chronic obstructive pulmonary disease (2015). 
Other patient conditions that could place a patient at an increased risk comprise cardiovascular, 
neuromuscular, kidney, and liver disease (Carron et al., 2016). Lastly, it has been established that 
geriatrics are also at an increased risk to PORC due to a decreased effectiveness in eliminating 
NMBAs and decreased respiratory compliance. The geriatric population remains highly 
prevalent at the designated facility in the Phoenix-Metropolitan area. In the State of Aging and 
Health in America 2013, the CDC predicts that by 2030 the geriatric population will account for 
nearly 72 million or 20% of the total US population. This is only complicated by the fact that 
nearly two out of every three geriatric patients have multiple comorbidities (CDC, 2013).  
Current Guidelines 
The significance of PORC in regards to patient safety and postoperative outcomes has 
been noted by several global specialty organizations worldwide. However, unlike our European 
counterparts, the American Society of Anesthesiologists (ASA) does not mandate the best-
practice of peripheral nerve monitoring for patients that received muscle relaxation (Brull & 
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Kopman, 2017). Furthermore, the current nationally accepted CPG for postanesthetic care does 
not include the use of sugammadex for reversal of blockade. The 2013 updated report by the 
ASA on Practice Guidelines for Postanesthetic Care states that “specific antagonists should be 
administered for reversal of residual neuromuscular blockade when indicated,” but only includes 
two approved acetylcholinesterase inhibitors, neostigmine and edrophonium (Apfelbaum et al., 
2013). Apfelbaum et al. (2013) identified the major premise of the CPG to evaluate current 
evidence-based recommendations for assessment, monitoring, and management with the goal to 
enhance patient safety for perioperative patients. The logical reasoning for sugammadex’s 
absence in the nationally recognized CPG is the date of revision, in that it was only recently 
approved in the US late 2015. In response to currently published literature, sugammadex’s 
inclusion into the ASA CPG as an appropriate reversal agent for patients recovering from 
rocuronium and vecuronium-induced neuromuscular blockade is imperative. Due to the non-
current, nationally published guidelines on postanesthetic care, there is an identified gap in 
current EBP and need for promotion of best-practices at the organizational level.  
Specific Institutional Focus 
This DNP project will take place in a specified healthcare organization in the Phoenix-
Metropolitan area. The main barrier to the implementation of sugammadex into the practice 
protocol is the perceived increase per patient cost of reversal. Current cost of reversal for an 
average 70-kilogram patient is $61 for 5 milligrams of neostigmine mixed with $36 for 1 
milligram of glycopyrrolate, for a total cost of $97 (Lexicomp, 2017). In comparison the current 
costs of sugammadex is $114 per patient, which is around $17 more than the neostigmine-
glycopyrrolate combination (Lexicomp, 2017). As the price differences vary from facility to 
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facility, it is estimated that there is an increased cost of $8 to $51 per reversal per patient 
(Lexicomp, 2018). However, this does not take into account the potential reduced perioperative 
stay costs and poor outcome treatment costs. Complications secondary to residual paralysis can 
significantly impact organizational budgets, in which the cost of managing postoperative patients 
with respiratory complications due to PORC was nearly $63,000 compared to only $5,000 for 
uncomplicated cases (Farhan et al., 2014). The overall reversal cost after all factors are 
considered does not produce a clear result, leading to the presumption that it could be highly 
beneficial to incorporate the use of sugammadex for high-risk patients. It is the healthcare 
organization’s responsibility to adapt current practices to the current, evidenced-based 
recommendations. Many of the anesthesia providers at the designated facility have vocalized 
their concerns to placing greater significance to minute increases in healthcare costs rather than 
evidence-based recommendations.  
Significance to Advanced Practice Nursing 
Data implies that PORC is a common concern for all perioperative patients that receive 
NMBAs, and demographic trends in the US are placing more and more patients at risk for poor 
postoperative outcomes. As DNPs are becoming mainstream in providing effective anesthesia 
care, it becomes essential that evidence-based recommendations are applied to clinical practice 
thus enhancing patient safety. It is the role of a DNP to continue propelling change forward for 
the betterment of our patient populations, and to integrate the best available research with 
clinical expertise through EBP (DiCenso, Guyatt, & Ciliska, 2005). CPGs are an integral 
component of EBP, in that they provide clear guidelines through evidence-based 
recommendations to promote patient care and the rate of successful patient management 
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(Zaccagnini & White, 2011). The role of DNPs also includes overcoming barriers of the status 
quo that might stand in the way of implementing best practices.  
The primary barrier to the full acceptance of sugammadex is the perceived increased cost, 
in that sugammadex is monetarily more expensive per vial. It is concerning that many healthcare 
organizations balance perceived profits with EBP, in which the perceived costs should be a 
nominal factor attributed to providing best practice to patients. A CPG for the regulated use of 
sugammadex could minimize this barrier for the many reluctant healthcare organizations and 
ensure that reversal agents are available for high risk patients and in emergent scenarios. 
Sugammadex should at minimum be made available in every healthcare organization for the 
occurrence of an NMBA overdose, similarly to naloxone being available for opioid overdose or 
flumazenil being available for benzodiazepine overdose. The unwillingness to implement the use 
of sugammadex, even if regulated, is a relative disregard and ignorance to EBP and places 
perioperative patients at risk.  
Purpose 
The purpose of this DNP project was to identify the current evidence-based 
recommendations from current literature for the reversal of neuromuscular blockade and develop 
a CPG at the organizational level with the input from anesthesia specialized consultants. The 
overall aim was to develop a high quality CPG ready for application in the clinical environment. 
The focus was on a facility without a CPG and was resistant to the full, unregulated use of 
sugammadex.  
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Study Question 
The project question for this DNP project is: Did the development of a CPG regarding the 
use of sugammadex produce quality-driven, evidence-based recommendations using efficient 
and transparent methodology with interdisciplinary applicability?  
FRAMEWORK AND SYNTHESIS OF EVIDENCE 
Theoretical Framework 
The overarching theory that guided this DNP project is Lewin’s Change Theory (LCT). 
The theory is considered one of the architypes to change theories, and has been utilized in 
numerous innovative changes (Kaminski, 2011). Changes in the clinical setting, such as the 
implementation of evidence-based recommendations in a CPG, are often pressured and chaotic 
which often leads to a lack of engagement from the operational stakeholders. This DNP project 
also utilized the Knowledge to Action (KTA) framework to implement the change in an effective 
manner. The inherent focus of the framework is to integrate research into practitioner’s practice 
as an instrument to enhance patient outcomes. The incorporation of theoretical frameworks 
allows a systematic and structured process for innovative change that reduces the risk of failure. 
The development of a CPG is a critical component to EBP in that it provides protocol driven 
recommendations, enhances treatment efficiency, and minimizes differences between 
practitioners (Tymkow, 2011). The incorporation of the LCT and KTA framework was ideal for 
this process as it describes the systematic approach to applying an innovative change agent into 
clinical practice.  
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Lewin’s Change Theory 
Developed in 1951 by Kurt Lewin, LCT recognizes that a change agent must navigate 
through three distinct phases prior to becoming a part of a healthcare organization (Mitchell, 
2013). The three phases that a change agent must traverse are the unfreezing phase, changing 
phase, and refreezing phase (Kaminski, 2011). However, the change agent must not only 
navigate through the three phases, but it must overcome resistance and barriers to change. LCT 
developed the key concept of force field analysis, which describes that all human behaviors are 
depended upon precarious forces that are either pushing us forwards or pulling us back from 
certain behaviors (Mitchell, 2013). There are three aspects to the force field analysis, which are 
the driving forces, the restraining forces, and equilibrium (Kaminski, 2011). Driving forces are 
those that guide use towards a change, which is opposed to restraining forces that propel us away 
(Kaminski, 2011). Equilibrium is reached at the point that the driving forces are equal to the 
restraining forces, and can be considered the status quo in many clinical scenarios (Kaminski, 
2011). The three phases of LCT provides a simple illustration of clinical change, assists with 
innovative change, and correlates specifically to the development of a CPG for the regulated use 
of sugammadex (Figure 1).  
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FIGURE 1. Adaptation of Lewin’s change theory.  
Unfreezing is the first phase of this theory, in which entails the examination of the status 
quo and current practices with identification of a need to change. The use of sugammadex in the 
perioperative phase for reversal of neuromuscular blockade has been a new concept for many 
practitioners, and is just starting to get traction. The recent literature support for sugammadex is 
a knowledge focused trigger that alerts practitioners to the ineffective, current practices. 
Knowledge focuses triggers include new published guidelines or research that recommends a 
change to how care is provided to enhance patient outcomes (Titler, 2010). It remains critical in 
the unfreezing phase to identify the driving forces in the early stages to push the change forward 
(Sutherland, 2013). Driving forces in this project include literature support of sugammadex’s 
simplicity of use and significantly improved patient outcomes. Restraining forces could include 
the hesitancy to changing the way it has always been done and inadequate knowledge to the 
efficiency of reversal with sugammadex. Enhancing the driving forces while diminishing the 
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restraining forces, such as with dialogue and education, will encourage the staff to let go of 
outdated practices (Kaminski, 2011).  
The change phase centers around the implementation of change into the clinical phase. 
This DNP project focused on the development of a CPG on the regulated use of sugammadex, 
from current evidence-based recommendations. The current, relevant evidence for sugammadex 
was assembled, analyzed, and synthesized, with verification that sufficient evidence is available. 
It would be beneficial during this phase to include a development timeline (Sutherland, 2013). 
The end goal of the change phase was to set a new equilibrium and move away from the status 
quo, which will need continually uplifting of driving forces. The CPG development included 
receiving input from an anesthesia consultant for a clinical expertise component. The primary 
restraining force to the incorporation of sugammadex into the perioperative phase is the fear of 
increased reversal costs per patient. This was minimized with the CPG’s focus on regulated use 
for high risk patients, instead of the notion that sugammadex needs to be used on every patient, 
every time. 
The establishment of the new guideline as a permanent practice in the perioperative phase 
would be evident in the last phase of refreezing (Kaminski, 2011). It was necessary to evaluate 
the CPG’s effectiveness and simplicity of use to ensure sustainability. To overcome the 
restraining force of knowledge and training deficit of the ancillary staff, it was appropriate 
ensure ease of use and applicability of the CPG. It is the responsibility of DNP prepared APRNs 
to take action in their own practice, make changes, and engage other practitioners to improve 
care (Mitchell, 2013). The use of LCT provided the overarching theoretical approach to change, 
by unfreezing the status quo of ineffective neuromuscular blockade reversal, implementing the 
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use of sugammadex through a CPG development, and sustaining change through application of 
high quality, literature supported guidelines.  
Knowledge to Action (KTA) Framework 
The KTA framework was designed to translate current evidence into current practice in 
an effective manner. Graham et al. (2006) highlighted that nearly 45% of patients are not 
receiving care according to current literature, and nearly 25% of patients are receiving 
interventions that are either ineffective or potentially harmful. APRNs need to be continually 
assessing current literature and enhancing their knowledge base with the intent to treat patients in 
an evidence-based approach, as opposed to solely working from previous clinical experience and 
perceived expertise (Doody & Doody, 2011). The KTA framework entails a step by step 
approach to implementing current evidence into a clinical setting to improve patient outcomes. 
This DNP project’s focus was to implement current evidence-recommendations on the use of 
sugammadex into anesthesia practice, and used the KTA framework as a systematic guide. The 
authors developed a knowledge to action process that incorporates knowledge creation and an 
action cycle for implementation (Graham et al., 2006).  
Knowledge creation is described as moving through a funnel, in that it becomes more 
refined and valuable for stakeholders as one delves through the research (Figure 2). The funnel 
begins with a knowledge inquiry that entails sifting through unmanageable amount of evidence, 
then moves into the synthesis of relevant and current literature (Graham et al., 2006). Knowledge 
synthesis describes the literature review of relevant and current evidence to the inquiry, and 
ensures that the evidence supports that actual change. It is strongly encouraged to incorporate 
systematic reviews and meta-analysis into this phase of knowledge creation (Graham et al., 
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2006). The final component of knowledge creation is the development of knowledge tools and 
products, such as seen with CPGs the provide clearly established recommendations (Graham et 
al., 2006). The overall goal in the first stage of the KTA framework for this DNP project was the 
development of a CPG on the regulated use of sugammadex.  
 
FIGURE 2. Adaptation of KTA knowledge creation.  
After the knowledge creation was completed with the development of a CPG, it 
underwent the action cycle of implementation to a clinical setting that applies an effective step 
by step approach (Figure 3). The initial steps in the action cycle includes the identification, 
selection, and adaption of knowledge at the organizational level (Graham et al., 2006). The 
designated facility was evaluated on its current practices and need for the regulated use of 
sugammadex. Assessing barriers to change was the next step to the action cycle (Graham et al., 
2006). There are numerous healthcare organizations that currently do not use sugammadex due 
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to the fear of increased costs per patient and change to ‘how it has always been done,’ however 
this is a great time to increase awareness of the issue and enhance driving forces. The next step 
included the tailoring of the CPG for applicability at the organizational, which was enhanced 
through inclusion of organizational insights from current anesthesia providers and key 
stakeholders (Graham et al., 2006). Further, this step included the adaption of the CPG with 
expert opinions. The last steps of the action cycle included evaluation of the quality of the CPG 
and methods to sustain the change (Graham et al., 2006). Evaluation of the CPG was provided 
via an CPG assessment tool. The sustained use of knowledge was encouraged with the CPG 
being made available to the healthcare organization and dissemination of results to its quality.  
 
FIGURE 3. Adaptation of KTA action cycle.  
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Synthesis of Evidence 
Search Strategy of Literature Review 
The literature review was conducted using highly credible electronic databases, including 
PubMED, CINAHL, and Cochrane Library. The search criteria focused on current 
recommendations and evidence pertaining to the use of sugammadex published since 2010 with 
full text availability. Evidence was appraised by its’ hierarchy of evidence, in that systematic 
reviews and meta-analyses were included as the highest quality studies followed by random 
controlled trials. Key search terms were included, but not limited to, sugammadex, neostigmine, 
neuromuscular blockade, obesity, geriatrics, liver disease, renal disease, sleep apnea, rapid 
sequence induction, safety, efficacy, and pediatrics. The search focus was specific to the DNP 
project and related to the use of sugammadex for the reversal of neuromuscular blockaded in the 
perioperative environment (Table 1). 
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TABLE 1. Synthesis of the effectiveness of sugammadex for reversal of neuromuscular blockade. 
Reference Purpose Study Design Sample/ Population 
Data Collection / 
Outcome Measures 
Findings/ Conclusion 
Abdulatif, Lotfy, Mousa, 
Afifi, & Yassen (2018) 
 
Sugammadex antagonism of 
rocuronium-induced 
neuromuscular blockade in 
patients with liver cirrhosis 
undergoing liver resection: 
a randomized controlled 
study.  
Compare the recovery time 
of sugammadex and 
neostigmine in reversal of 
rocuronium induced NMB 
in patients with liver 
cirrhosis and controls 
undergoing liver resection.  
Randomized 
control trial.  
27 patients with Child-Pugh 
class “A” liver cirrhosis and 
28 patients with normal 
liver function, all from ages 
18 to 60 years undergoing 
liver resections (N= 55).  
 
Group 1(n= 14): Patients 
with normal liver function 
that received sugammadex.  
 
Group 2 (n= 14): Patients 
with normal liver function 
that received neostigmine. 
 
Group 3 (n= 13): Patients 
with liver cirrhosis that 
received sugammadex. 
 
Group 4 (n= 14): Patients 
with liver cirrhosis that 
received neostigmine. 
 
Ethical approval and patient 
consent.  
Data collection performed 
using SPSS for Windows. 
Numerical values 
summarized as means. 
- ANOVA 
- Post-hoc Tuckey test 
- Chi-square test 
- Fisher’s Exact test 
 
Compare the reversal of 
rocuronium induced NMB 
with sugammadex and 
neostigmine.  
Primary outcome:  
- Time from antagonist 
administration to a TOFR > 
0.9.  
Secondary outcomes: 
- Durations of intubating 
and top up doses of 
rocuronium.  
- Length of stay in the 
PACU.  
- Incidence of postoperative 
recurarization.  
 
There was a faster recovery time for 
patients with sugammadex reversal 
for patients with liver disease (3.1 
min) and normal liver function (2.6 
min) compared to patients reversed 
with neostigmine with liver disease 
(14.5 min) and normal liver function 
(15.7 min; p<0.001).  
 
There was a shorter stay in PACU 
for patients reversed with 
sugammadex for patients with liver 
disease (23 min) and normal liver 
function (22.8 min) compared to 
patients reversed with neostigmine 
with liver disease (43.9 min) and 
normal liver function (43.2 min; 
p<0.001).  
 
Conclusion: sugammadex rapidly 
reverses rocuronium induced NMB 
in patients with Child-Pugh class 
“A” liver cirrhosis undergoing liver 
resection.  
Carron, Zarantonello, 
Lazzarotto, Tellaroli, & Ori 
(2017) 
 
Role of sugammadex in 
accelerating postoperative 
discharge: A meta-analysis.  
 
To review and evaluate the 
evidence comparing 
sugammadex and 
neostigmine related to 
patient discharge after 
general anesthesia.  
Systematic 
review and 
meta- 
analysis. 
  
Study design 
using 
PRISMA 
methodology.  
 
Six randomized controlled 
trials.  
 
Patients totaling 518.  
 
Setting in a university 
medical hospital.  
 
Comprehensive literature 
search conducted using 
PubMed, Web of Science, 
Google Scholar, and 
Cochrane Library 
electronic databases.  
 
Measurement of time to 
discharge after a NMB 
reversal with sugammadex 
compared to neostigmine.  
 
Discharge from the OR to PACU 
was significantly faster with 
sugammadex (MD= 22.14 min; 95% 
CI; P < 0.00001).  
 
Discharge from the OR to PACU 
with deep NMB had even greater 
recovery with sugammadex (MD= 
30.05 min; 95% CI; P < 0.002).  
 
Discharge from the PACU to 
surgical ward was significantly  
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Reference Purpose Study Design Sample/ Population 
Data Collection / 
Outcome Measures 
Findings/ Conclusion 
    - Discharge from the OR 
to the PACU.  
- Discharge from the OR 
to the PACU with deep 
NMB.  
- Discharge from the 
PACU to surgical ward.  
- Discharge of morbidly 
obese patients from the 
PACU to surgical ward.  
 
faster with sugammadex (MD= 
16.95 min; 95% CI; P= 0.0469). 
Discharge of morbidly obese 
patients from the PACU to surgical 
ward was significantly increased 
with the use of sugammadex (MD= 
8.75 min; 95% CI; P < 0.0001).  
 
Conclusion: sugammadex 
accelerates postoperative discharge 
of patients after general anesthesia 
compared to neostigmine. 
 
Carron, Zarantonello, 
Tellaroli, & Ori (2016) 
 
Efficacy and safety of 
sugammadex compared to 
neostigmine for reversal of 
neuromuscular blockade: a 
meta-analysis of 
randomized controlled 
trials.  
 
To review and evaluate the 
evidence related to the 
effectiveness and safety of 
sugammadex compared to 
neostigmine for reversing 
NMB in adults.  
Meta-analysis. 
  
Study design 
using PRISMA 
methodology. 
Thirteen randomized 
controlled trials.  
 
Patients totaling 1384.  
 
Setting in a university 
medical hospital.  
 
Comprehensive literature 
search conducted using 
PubMed, Web of 
Science, and Cochrane 
Library for electronic 
databases. Only included 
English-language 
articles.  
 
Measurement of 
sugammadex compared 
to neostigmine on 
reversing NMB.  
Primary outcomes: 
- Speed of reversal.  
- TOFR after reversal of 
NMB.  
Secondary outcomes: 
- Risk of postoperative 
residual recurarization 
after extubation.  
- Risk of global adverse 
events. 
- Postoperative nausea 
and vomiting.  
- Reported pain.  
Speed of recovery was significantly 
faster with sugammadex (MD= -
1.79 min; 95% CI, P < 0.0001).  
 
TOFR was assessed significantly 
higher with the use of sugammadex 
after reversal (MD= 0.18; 95% CI; P 
< 0.0001).  
 
Sugammadex was found to have a 
significantly lower risk of 
postoperative residual recurarization 
(OR= 0.05; 95% CI; P = 0.0068), 
global adverse events (OR= 0.47; 
95% CI; P < 0.0001), respiratory 
adverse events (OR= 0.36; 95% CI; 
P = 0.0386), cardiovascular adverse 
events (OR= 0.23; 95% CI; P = 
0.0036), and postoperative weakness 
(OR= 0.45; 95% CI; P = 0.0409).  
 
No significant differences between 
sugammadex and neostigmine on 
postoperative nausea and vomiting, 
pain, neurological adverse events, 
and change in laboratory test values.  
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    - Risk of neurological 
adverse events.  
- Changes in laboratory 
test values. 
 
Conclusion: sugammadex is 
superior to neostigmine due to its 
speedier recovery and lower risk of 
adverse events. 
 
Chambers, Paulden, Paton, 
Heirs, Duffy, Hunter, 
Sculpher, & Woolacott (2010) 
 
Sugammadex for reversal of 
neuromuscular block after 
rapid sequence intubation: a 
systematic review and 
economic assessment.  
 
Review and evaluate the 
evidence on the efficacy 
and cost-effectiveness for 
the use of sugammadex for 
reversal of NMB after RSI.  
Systematic 
review.  
 
Three random- controlled 
trials.  
 
Patients totaling 336 
adults.  
 
 
Comprehensive literature 
search conducted using 
MEDLINE, CINAHL, 
Science Citation Index, 
BIOSIS, EMBASE, and 
CENTRAL for electronic 
databases.  
 
Two placebo controlled 
trials to compare the use 
of sugammadex to 
reverse RSI dose of 
rocuronium to that of a 
placebo (spontaneous 
recovery).  
 
One controlled-trial to 
compare the RSI of 
rocuronium/ 
sugammadex to 
succinylcholine with 
spontaneous recovery. 
- Time to recovery 
assessed by T1/T10=0.1 
- Time from start of 
NMBA to TOFR > 0.9 
- Time of sugammadex 
administration to TOFR 
> 0.9 
 
Sugammadex was found to 
significantly reduce the time of 
reversal from a RSI dose of 
rocuronium from 90-120 min.  
 
Patients that received 
rocuronium/sugammadex RSI 
compared to succinylcholine had 
significantly time of T1/T10 (4.4 
min to 7.1 min) and to TOFR > 0.9 
(6.2 min vs. 10.9 min). Time from 
sugammadex administration to 
TOFR > 0.9 was 2.2 min (P < 
0.00001).  
 
Limited economic assessment due to 
lack of suitable evidence. 
 
Conclusion: the use of sugammadex 
for the reversal of rapid sequence 
induction dose of rocuronium is 
effective.  
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Evron, Abelansky, Ezri, & 
Izakson (2017) 
 
Respiratory events with 
sugammadex vs. neostigmine 
following laparoscopic sleeve 
gastrectomy: a prospective 
pilot study assessing 
neuromuscular reversal 
strategies.  
Determine if the use of 
sugammadex compared 
to neostigmine would 
result in lower 
respiratory events for 
obese patients 
undergoing sleeve 
gastrectomy surgeries.  
Randomized 
control trial. 
N= 57 obese patients 
undergoing laparoscopic 
sleeve gastrectomy. 
Inclusion criteria included 
ASA classification I-III, > 
18 years of age, without 
neuromuscular, renal, or 
liver disease.  
 
Group 1 (n= 32): 
Patients received reversal 
from NMB with 2 mg/kg 
of sugammadex.  
 
Group 2 (n= 25):  
Patients received reversal 
from NMB with 
neostigmine 2.5 mg.  
 
Single site study in 
Hollon, Israel. 
 
Ethical approval through 
IRB and patient consent. 
 
Data collection 
performed using SPSS 
for Windows. Numerical 
values summarized as 
means. 
- Kolmogorov-Smirnov 
test 
- chi-square test 
- t test 
- Fisher exact test 
 
Measurement of groups 
were compared related to 
the reversal of 
sugammadex to 
neostigmine for 
rocuronium-induced 
NMB.  
- Oxyhemoglobin 
saturation in the PACU.  
- TOF counts prior to 
administration of reversal 
agent.  
- Unexpected ICU 
admissions.  
- Incidences of 
reintubation. 
 
Oxyhemoglobin saturation was 
significantly higher in the PACU 
with the use of sugammadex 
compared to the neostigmine group 
(96.72 vs. 95.80; p < 0.01).  
 
Minimal oxyhemoglobin saturation 
was lower in the neostigmine group 
at 93% compared to 94% in the 
sugammadex group (p= 0.01).  
 
TOF count was significantly lower 
in the sugammadex group prior to 
administration of the reversal agent 
compared to the neostigmine group 
(2.53 vs 3.48; p < 0.01).  
 
Conclusion: The use of 
sugammadex for reversal of NMB 
compared to neostigmine was 
associated with higher 
oxyhemoglobin saturation, despite 
lower TOF count prior to reversal. 
 
Hristovska, Duch, Allingstrup, 
& Afshari (2017) 
 
The comparative efficacy and 
safety of sugammadex and 
neostigmine in reversing 
neuromuscular blockade in 
adults. A Cochrane systematic 
review with meta-analysis and 
trial sequential analysis.  
Review and evaluate 
the evidence for 
effectiveness of 
sugammadex in 
reversal of NMB 
compared to 
neostigmine for adult 
patients undergoing 
general anesthesia.  
Systematic 
review and 
meta-analysis.  
 
Study design 
using PRISMA 
methodology. 
41 randomized controlled 
trials.  
 
Patients totaling 4,206 
patients.  
Comprehensive literature 
search conducted using 
CENTRAL, MEDLINE, 
and Embase for 
electronic databases. 
 
Compared the efficacy of 
sugammadex and 
neostigmine.  
Time of reversal of NMB was 
significantly faster with 
sugammadex from 2nd twitch to 
TFOR > 0.9 (2.0 min vs. 12.9 min; 
MD 10.2; 95% CI).  
 
Time of reversal of NMB was 
significantly faster with 
sugammadex from post-tetanic 
count 1-5 to TOFR > 0.9 (2.9  
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    Primary outcomes: 
- Recovery time from 
2nd twitch to TOFR > 
0.9.  
- Recovery time from 
post-tetanic count1-5 to 
TOFR > 0.9.  
Secondary outcomes: 
- Risk of drug-induced 
adverse events.  
- Risk of serious adverse 
events.  
 
min vs. 48.8 min; MD 45.8; 
95% CI).  
 
Sugammadex had significantly 
less drug-induced adverse events 
(RR 0.60; 95% CI). Specifically, 
less bradycardia (RR 0.16; 95% 
CI), PONV (RR 0.52; 95% CI), 
and residual paralysis (RR 0.40; 
95% CI). There was no 
significant difference in serious 
adverse events.  
 
Conclusion: sugammadex 
reverses NMB more rapidly than 
neostigmine and is associated 
with fewer adverse events. 
 
Liu, Wang, Yan, Fan, Xue, & 
Wang (2017) 
 
The efficacy and safety of 
sugammadex for reversing 
postoperative residual 
neuromuscular blockade in 
pediatric patients: A 
systematic review.  
 
Review and evaluate the 
evidence on the efficacy and 
safety of sugammadex for 
reversing NMB in pediatric 
patients.  
Systematic 
review, and 
meta-analysis. 
 
Study design 
using PRISMA 
methodology. 
Ten randomized controlled 
trials.  
 
Patients totaling 580 
pediatric patients.  
 
Setting in a medical 
hospital in Beijing, China.  
 
Comprehensive 
literature search 
conducted using 
MEDLINE, PubMed, 
Web of Science, 
EMBASE, and 
CENTRAL for 
electronic databases.  
 
Primary outcome: 
- Time interval from 
administration of 
reversal agent to TOFR 
> 0.9.  
 
Secondary outcome: 
- Incidences of any 
drug-related adverse 
events.  
There was a significantly 
reduced time to TOFR > 0.9 for 
pediatric patients that received 
sugammadex compared to 
neostigmine (WMD= -8.51 min; 
95% CI). 
 
There was a significantly 
reduced risk of drug-induced 
bradycardia with the use of 
sugammadex compared to 
neostigmine (RR= 0.08; 95% 
CI).  
 
There was not a significant 
change related to nausea and 
vomiting, diarrhea, and 
bronchospasm.  
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     Conclusion: compared to 
neostigmine or a placebo, 
sugammadex reverses 
rocuronium-induced NMB in 
pediatric patients rapidly and 
safely. 
 
McDonagh, Benedict, Kovac, 
Drover, Brister, Morte, & 
Monk (2011)  
 
Efficacy, safety, and 
pharmacokinetics of 
sugammadex for the reversal 
of rocuronium-induced 
neuromuscular blockade in 
elderly patients.  
Compare the efficacy, safety, 
and pharmacokinetics of 
sugammadex administration 
for reversal of moderate NMB 
in adults vs. elderly patients.  
Prospective, 
randomized 
control trial.  
N= 150 adult patients 
undergoing general 
anesthesia requiring 
NMB, with ASA 
classification I-III.  
 
Group 1 (n= 48): 
Adult patients aged 18-64 
years old.  
 
Group 2 (n= 62):  
Elderly patients aged 65-
74 years old.  
 
Group 3 (n= 40): 
Old-elderly patients aged 
> 74 years old.  
 
Multicenter, 14 surgical 
centers in the United 
States.  
 
Ethical approval and 
patient consent. 
 
Data collection 
performed using SPSS 
for Windows.  
- two-way ANOVA 
model 
 
Measurement of groups 
were compared related 
to the reversal of 
rocuronium induced 
NMB with 
sugammadex 2 mg/kg.  
- Time from the 
administration of 
reversal to TOFR > 0.9.  
Time from administration of 
sugammadex to a TOFR > 0.9 
was increased the most in old-
elderly/elderly groups (2.7-3.2 
min) than the adult group (2.0-
2.6 min; P= 0.022). Recovery 
was estimated to be 0.7 min 
faster in adults compared to 
patients 65 years and older.  
 
Sugammadex was tolerated by 
all patients, no adverse events 
were noted.  
 
Conclusion: sugammadex 
reverses rocuronium-induced 
NMB rapidly and safely in 
adults of all ages.  
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Robertis, Marinosci, Romano, 
Piazza, Iannuzzi, Cirillo, 
Simone, & Servillo (2016) 
 
The use of sugammadex for 
bariatric surgery: analysis of 
recovery time from 
neuromuscular blockade and 
possible economic impact.  
 
Compare recovery times after 
the administration of 
sugammadex and neostigmine, 
and assess the possible 
economic impact. 
Retrospective, 
non-randomized 
study. 
 
N= 95 morbidly obese 
patients (body mass index 
> 40 kg/m2) undergoing 
bariatric surgery.  
 
Group 1 (n= 50): 
Obese patients that 
received rocuronium and 
sugammadex for NMB 
and reversal. 
 
Group 2 (n= 49): 
Obese patients that 
received either 
rocuronium or 
cisatracurium and 
neostigmine for NMB and 
reversal.  
 
Single surgical center in 
Naples, Italy.  
 
Local ethics approval by 
the University of Naples 
Federico II approved. 
 
Data collection 
performed using SPSS 
for Windows.  
- Wilcoxon rank sum 
test 
- Mann-Whitney U test 
 
Measurements were 
made to compare the 
reversal of 
sugammadex to 
neostigmine in 
recovery of NMB.  
- Mean recovery time 
from reversal to a 
TOFR > 0.9.  
- Mean theater 
occupancy (time from 
the start of anesthesia 
time until the time the 
patient was transported 
to the PACU).  
- Mean time to obtain 
an Aldrete score of 10 
(indication that the 
patient is ready to be 
discharged from the 
PACU).  
  
The mean recovery time was 
significantly faster in the 
sugammadex group than the 
neostigmine group (1.4 min vs. 
26.4 min, P < 0.05). All patients 
that received sugammadex had 
received a TOFR > 0.9 within 5 
minutes.  
 
The mean theater occupancy 
time was significantly faster in 
the sugammadex group than the 
neostigmine group (93.3 min vs. 
116.6 min, P < 0.05).  
 
The mean time to achieve an 
Aldrete score of 10 was 
significantly faster in the 
sugammadex group than the 
neostigmine group (16 min vs. 
21.8 min, P < 0.05).  
 
Conclusion: reversal from NMB 
is significantly faster in obese 
patients with sugammadex 
compared to neostigmine.  
Souza, Tardelli, Tedesco, 
Garcia, Caparros, Alvarez-
Gomez, & Oliveira (2015)  
 
Efficacy and safety of 
sugammadex in the reversal of 
deep neuromuscular blockade 
induced by rocuronium in 
patients with end-stage renal 
disease: 
Compare the efficacy and 
safety of sugammadex 
administration for reversal of 
profound NMB in patients 
with renal failure and normal 
renal function.  
Prospective, 
randomized 
control trial.  
N= 40 patients undergoing 
kidney transplantation.  
 
Group 1 (n= 20): 
Patients with renal failure 
as defined as a creatinine 
clearance < 30.  
 
Group 2 (n= 20):  
Data collection 
performed using SPSS 
for Windows.  
 
- Kolmogorov-Smirnov 
test 
- Chi-square test 
- t test 
- Fisher exact test 
- Mann-Whitney test 
The mean time for reversal of 
NMB from sugammadex was 
prolonged in the patients with 
renal failure (5.6 min) compared 
to the normal renal function 
group (2.7 min; P= 0.003).  
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A comparative prospective 
clinical trial. 
  Patients with with normal 
renal function as defined 
as a creatinine clearance > 
90.  
 
Two university hospitals 
in Sao Paulo, Brazil. 
 
Ethical approval and 
patient consent. 
 
Measurement of 
groups were compared 
related to the reversal 
of rocuronium induced 
NMB with 
sugammadex.  
- Time from 
rocuronium to NMB.  
- Time from the 
administration of 
reversal to TOFR > 
0.9.  
- Adverse events 
related to NMB. 
 
No adverse events or evidence 
of recurarization of NMB were 
observed.  
 
Conclusion: Sugammadex 
effectively and safely reverses 
profound rocuronium induced 
NMB in patients with renal 
disease, however recovery is 
slightly prolonged. 
Unal, Baran, Mutlu, Ural, 
Akkaya, & Ozlu (2015) 
 
Comparison of 
Sugammadex versus 
Neostigmine Costs and 
Respiratory Complications 
in Patients with Obstructive 
Sleep Apnoea.  
 
Compare the efficacy of 
sugammadex and neostigmine 
in reversing rocuronium 
induced NMB.  
Randomized, 
control trial.  
N= 74 patients with ASA 
classification of I or II, 
with a diagnosed history 
of obstructive sleep apnea.  
 
Group S (n= 37): 
Patients received reversal 
from NMB with 2 mg/kg 
of sugammadex.  
 
Group N (n= 37):  
Patients received reversal 
from NMB with 
neostigmine 0.04 mg/kg.  
 
Research hospital in 
Kayseri, Turkey. 
 
Ethical approval and 
patient consent. 
Data collection 
performed using SPSS 
for Windows. 
Numerical values 
summarized as means. 
- Shapiro-Wilk test 
- Levine’s test 
- Mann-Whitney U 
test 
- chi-square test 
 
Measurement of 
groups were compared 
related to the reversal 
of sugammadex to 
neostigmine for 
rocuronium-induced 
NMB.  
- TOFR after reversal.  
- OR time.  
- PACU stay.  
- Postoperative 
respiratory 
complications.  
There was a significant faster 
time to reach TOFR of 0.9 in 
group S (2 min vs. 8 min, p < 
0.0001).  
 
There was a significant 
reduction in OR (72.4 min vs. 
96.6 min, p < 0.001) and 
PACU times (22.9 min vs. 36.3 
min, p < 0.001).  
 
There was a significant 
increase in respiratory 
complications in Group N, 
including desaturation (12 vs. 
3, P = 0.048), airway 
manipulation (12 vs. 3, P = 
0.021), Re-intubation (3 vs. 0, 
P = 0.021), and use of CPAP 
device (12 vs. 3, P = 0.028).  
 
The cost of reversal was greater 
in Group S (6147.88 TL vs. 
3569.5 TL), however the cost  
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TABLE 1 – Continued  
Reference Purpose Study Design Sample/ Population 
Data Collection / 
Outcome Measures 
Findings/ Conclusion 
    - Costs related to 
NMB reversal, 
anesthesia care, and 
treatment. 
 
of complication treatment was 
less (199.5 TL vs. 3944.6 TL). 
The total cost was less in 
Group S compared to Group N 
(6347.38 TL vs. 7514.15 TL).  
 
Conclusion: sugammadex 
decreases the incidences of 
postoperative respiratory 
complications and related costs 
in patients with obstructive 
sleep apnea. 
 
PRISMA= Preferred Reporting Items for Systematic Reviews and Meat-Analyses; NMB= Neuromuscular Blockade; OR = Operating room; PACU= Postoperative Care Unit; 
MD= Mean difference; CI= Confidence Interval; TOFR= Train-of-four ratio; OD= Odds ratio; WMD= Weighted mean difference; RR= Risk ratio; SPSS= Statistical Package for 
the Social Sciences; ASA= American Society of Anesthesiologists; CPAP= Continuous positive airway pressure; TR= Turkisch Lira; RIS= Rapid Sequence Induction; MD= Mean 
difference; PONV= postoperative nausea and vomiting. 
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Sugammadex Reversal in the Perioperative Environment 
Sugammadex has been studied extensively related to the reversal of neuromuscular 
blockade compared to current reversal practices, and has shown unprecedented effectiveness. A 
recent meta-analysis was completed assessing surgical times comparing sugammadex and 
neostigmine, and found that sugammadex speed up discharge in adult surgical patients from the 
operating room (OR) to the postoperative care unit (PACU) by 22 minutes for normal 
neuromuscular blockade and 30 minutes for deep neuromuscular blockade (Carron, Zarantonello, 
Lazzarotto, Tellaroli, & Ori, 2017). Another recent meta-analysis compared the effectiveness of 
sugammadex to neostigmine, and found that it accelerated time to a train-of-four ratio (TOFR) of 
greater than 90% by nearly 9 minutes in pediatric surgical patients (Liu et al., 2017). Robertis et 
al. (2016) found that sugammadex increased recovery from neuromuscular blockade 25 minutes 
quicker than neostigmine in morbidly obese patients, and reduced the OR time by 23 minutes. 
Another recent meta-analysis compared the effectiveness of sugammadex compared to 
neostigmine in adult surgical patients, inclusion of 41 separate randomized controlled trials and 
over 4,200 patients, and found that reversal time was increased by 11 minutes from the second 
twitch to a TOFR greater than 90%, and was surprisingly increased by 46 minutes from a post-
tetanic count of 1-5 to a TOFR greater than 90% (Hristovska, Duch, Allingstrup, & Afshari, 
2017). There is substantial amount of evidence that supports that sugammadex is significantly 
more superior compared to current reversal practices, which is this literature review’s 
predominant strength.  
Another strength to this literature review is the evidence that supports sugammadex 
significantly lowers the risk of perioperative adverse events related to drug-induced reactions and 
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recurarization, as specified in three different systematic reviews (Carron et al., 2017; Hristovska 
et al., 2017; Liu et al., 2017). Carron et al. (2017) assessed for adverse events related to PORC 
and found that sugammadex lowered the risk of global adverse events, respiratory adverse 
events, cardiovascular adverse events, and postoperative weakness. Some of the respiratory 
adverse events that were monitored and reduced in these studies included hypoxemia, pulmonary 
edema, reintubation, upper airway obstruction, and respiratory failure (Carron et al., 2017). Unal 
et al. (2015) found that the use of sugammadex reduced the risk of postoperative desaturation, 
airway manipulation, reintubation, and continuous positive airway pressure requirement in 
patients with obstructive sleep apnea. One study found that sugammadex significantly increased 
the oxyhemoglobin saturation of obese surgical patients in the postoperative stage despite a 
lower TOFR prior to reversal (Evron, Abelansky, Ezri, & Izakson, 2017). Some of the 
cardiovascular adverse events that were reduced with the use of sugammadex included 
bradycardia, cardiac arrhythmias, and variable atrial pressures (Carron et al., 2017). Three 
separate meta-analyses found that the use of sugammadex significantly reduced the risk of drug-
induced bradycardia in both pediatric and adult surgical patients (Carron et al., 2017; Hristovska 
et al., 2017; Liu et al., 2017). Sugammadex was also associated with a significantly reduced risk 
of PORC and postoperative weakness (Carron et al., 2017; Hristovska et al., 2017). One of the 
weaknesses in the literature review is the conflicting data pertaining to if sugammadex reduced 
the incidence of postoperative nausea and vomiting (PONV). One meta-analysis found that 
sugammadex reduced the incidence of PONV in adult surgical patients, however it expressed its 
concerns related smaller patient population and limited quality of evidence (Hristovska et al., 
2017). Two other meta-analyses did not find a significant reduction in the incidence of PONV 
   
42 
related to sugammadex for both pediatric and adult surgical patients (Carron et al., 2017; Liu et 
al., 2017). Overall, sugammadex has been associated with reducing postoperative weakness and 
the risk of numerous adverse events, however there is limited evidence to support that 
sugammadex reduces the risk of PONV. 
Sugammadex has also been attributed to ensuring a complete, effective reversal from 
neuromuscular blockade in patients that are considered at a high risk of postoperative 
complications with certain comorbidities. Sugammadex effectively reverses neuromuscular 
blockade in morbidly obese surgical patients and is associated with quicker reversal times, 
shorter anesthesia time, and higher postoperative saturation (Robertis et al., 2016; Evron et al., 
2017). One of the patient populations that is at an increased risk of postoperative respiratory 
complications includes patients with obstructive sleep apnea, in which sugammadex has been 
associated with quicker, effective reversal and lower risk of postoperative respiratory risks (Unal 
et al., 2015). Sugammadex has also been found to effectively reverse patients with end-stage 
renal failure surgical patients without any incidence of adverse event or recurarization (Souza et 
al., 2015). Even though the elderly and old-elderly surgical patients have a slightly prolonged 
recovery times, one study found that sugammadex has been shown to effectively reverse 
neuromuscular blockade without any documented adverse events (McDonagh et al., 2011). The 
use of sugammadex has further been attributed to adequate reversal of neuromuscular blockade 
in patient with liver disease, and is associated with faster recovery times and shorter stay in the 
PACU (Abdulatif, Lotfy, Mousa, Afifi, & Yassen, 2018). 
Sugammadex can be used to reverse a rapid sequence induction dose of rocuronium 
effectively, and limit the risk of a CVCI event. Sugammadex administered 3 minutes after 1.2 
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mg/kg dose of rocuronium significantly increased recovery from deep neuromuscular blockade 
compared to a rapid-sequence induction dose of succinylcholine by 4 minutes (Chambers et al., 
2010). The authors further identified that full reversal from a large dose of rocuronium only took 
a mean time of 2.2 minutes in which other reversal strategies are contraindicated, in which can 
eliminate the life-threatening risk of a CVCI scenario. 
There is a current gap in the literature related to the cost effectiveness of reversal with 
sugammadex as the sole reversal agent for rocuronium and vecuronium induced neuromuscular 
blockade. This is a complicated topic because the cost of the reversal agent is not the only factor 
to deduce what the overall cost is for the patient, in which sugammadex is more expensive per 
dose compared to neostigmine. However, sugammadex has been found to significantly reduce 
the risk of postoperative adverse events and reduced time in the operating rooms and 
postoperative care units, which theoretically can reduce the overall care costs. In certain singles 
site studies, it has been advised that the use of sugammadex for patients with morbid obesity or 
obstructive sleep apnea can reduce the total cost to the patient by reducing the risk of 
complications and time in recovery (Robertis et al., 2016; Unal et al., 2015). There is limited 
research to support that sugammadex is cost effective and reduces overall surgical costs for all 
surgical patients in every clinical scenario, primarily due to the increased in cost per reversal 
dose. 
Overall, sugammadex has been found to reverse the effects of neuromuscular blockade 
more effectively and timely compared to currently used reversal agents. Sugammadex has been 
associated with the safe use reversing rapid sequence induction doses of rocuronium which can 
lead to a significant reduction in the incidences of CVCI scenarios. It has been effective at 
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reversing neuromuscular blockade in high risk patient populations, which includes patients with 
morbid obesity, obstructive sleep apnea, advanced age, cardiovascular disease, chronic renal 
failure, chronic liver failure, and neuromuscular disease. Furthermore, sugammadex has been 
correlated with fewer perioperative adverse effects compared to current reversal practices. 
METHODS 
Design 
This project was guided by the KTA framework and LCT resulting in the development of 
a CPG for sugammadex. Recommendations were adapted from the literature search and 
evaluated by anesthesia providers using the Appraisal of Guidelines for Research & Evaluation 
II (AGREE II) Instrument to assess for quality and validity (Brouwers et al., 2010). The My 
AGREE PLUS, an electronic version of the assessment tool, was used. The CPG and results 
were made available to the designated facility for implementation. 
Setting and Participants 
This project took place in the Phoenix-Metropolitan area with a convenience sample of 
volunteer anesthesia providers currently practicing. The AGREE II Instrument recommends that 
the guideline is assessed by at least two appraisers and preferably four to increase reliability 
(Brouwers et al., 2010). Four anesthesia providers (N=4) were included in the My AGREE 
PLUS evaluation process. Each of the participants were experienced Certified Nurse Anesthetists 
(CRNAs) whom are currently using sugammadex in their practice. To reduce the risk of a biased 
evaluation, all participants that were either full-time employees at the designated facility or were 
involved with the development of the CPG were strictly excluded from the evaluation process.  
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Key Stakeholder Involvement 
Key anesthesia stakeholders at the designated facility were also involved in this DNP 
project. One key stakeholder at the designated facility, a CRNA with experience on the Banner 
University Anesthesia Consensus Committee, was selected to provide expert opinion to help 
tailor the guideline to the facility. Key leaders were also involved in this DNP Project, including 
the Director of Anesthesia and the Chief CRNA. Both leaders expressed unprecedented support 
to the use of sugammadex in the perioperative phase, however the facility has been cautious in 
accepting sugammadex due to perceived increase of reversal costs. To clarify, a total of three 
stakeholders, one anesthesiologist and two CRNAs, were involved throughout the development 
of this DNP project and provided pertinent organizational insight to enhance applicability.  
Guideline Development 
The development of the CPG on the regulated use of sugammadex followed the AGREE 
II framework, which is a systematic process to improve the quality of practice guidelines. The 
AGREE Reporting checklist was utilized during the development phase of the CPG (Appendix 
C). The AGREE Reporting checklist provides specific reporting criteria for each domain and 
question that the AGREE II tool assesses. The intent is to assist clinicians to ensure completeness 
and transparency when reporting CPGs. The current recommendations on the use of 
sugammadex were summarized in an easy to understand and follow guideline. An anesthesia 
provider championed the CPG development in collaboration with the author to ensure that 
current practices and applicability of the recommendations are considered. The anesthesia 
provider had valuable pharmacy input on facilitators and barriers to sugammadex 
implementation. This information was vital for the interdisciplinary applicability of the 
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developed CPG. It is highly recommended that content area experts are included, such as 
anesthesia providers, in the development and appraisal of guidelines to increase both quality of 
evaluation and comprehension of the CPG (Brouwers et al., 2010). This CPG incorporated 
evidence based recommendations on adequately reversing patients that have received either 
rocuronium or vecuronium induced neuromuscular blockade that results in patient scenarios of 
CVCI, inadequately reversed neuromuscular blockade, premature termination of surgical 
procedure, or high risk of postoperative complications (Appendix D). 
Level of Evidence 
The level of evidence and grade of recommendations were evaluated during the 
developing phase to ensure transparency. The level of evidence was determined using the Levels 
of Evidence for Therapeutic Studies (Figure 4). The level of evidence is taken into account when 
grading the specific recommendations on the CPG (Burns, Rohrich, & Chung, 2011). The use of 
systematic review of RCTs is the highest level of evidence, with the use of case series and expert 
opinion at the lowest level (Burns, Rohrich, & Chung, 2011). After the level of evidence is 
quantified, the principle investigator (PI) was able to determine the strength or lack thereof of the 
recommended intervention. The grading of the recommendations was accomplished using an 
adaption of the Grade Practice Recommendations (Figure 5).  
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FIGURE 4. Adaptation of levels of evidence for therapeutic studies.  
 
 
 
FIGURE 5. Adaptation of grade practice recommendations.  
Tools 
he CPG development underwent the AGREE II framework, which is a systematic tool to 
improve the variability in the quality of practice guidelines (Brouwers et al., 2010). The AGREE 
II Instrument was utilized for appraisal of the practice guidelines. The AGREE Research Trust 
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provided valuable online training, references, and free downloads for the appraisers. The 
website’s address is https://www.agreetrust.org/ 
AGREE II 
The AGREE Instrument was first established to create a generic tool to assess the process 
of guideline development and evaluate quality. The goal of the tool is to ensure that only the 
highest quality CPGs are implemented into practice, which aims at helping providers develop 
policy and system-related decisions. The AGREE Instrument was first developed in 2003 by the 
AGREE Collaboration to describe the three components of quality in a CPG, which includes 
addressing any biases, internal and external validity, and realistic implementation into practice 
(Brouwers et al., 2010). The AGREE II Instrument is intended for use by numerous stakeholder 
groups, which includes healthcare providers, guideline developers, policy makers, and educators 
(Brouwers et al., 2010). Healthcare providers are able to use the AGREE II Instrument to assess 
newly developed practice guidelines prior to adopting them into clinical practice. It is designed 
for CPGs at the local, regional, or national organizational levels pertaining to any clinical 
specialty within any step of the healthcare continuum (Brouwers et al., 2010). The instrument 
has since been refined to improve its’ usability, validity, and reliability. In order to meet the three 
components, they created a 23-item tool that evaluated six separate quality domains of newly 
established practice guidelines (Appendix D). The six domains include (1) the scope and 
practice, (2) stakeholder involvement, (3) rigor of development, (4) clarity of presentation, (5) 
applicability, and (6) editorial independence. As well the AGREE II tool establishes two final 
overall assessment items that guide the appraiser to identify overall judgements of the CPG 
(Brouwers et al., 2010).  
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Domain 1. Scope and purpose. The authors included items 1-3 in this domain which is 
concerned with the overall aim of the CPG, the specific health questions, and the target 
population. The overall goal of the CPG should be clearly identified in detail and related to the 
clinical problem associated with the targeted patient population. The CPG should clearly 
establish the expected benefits or outcomes associated with applications of the practice 
guidelines. The CPG should identify exactly which patient population is included under the 
guidelines, and exclude populations if relevant (Brouwers et al., 2010). 
Domain 2. Stakeholder involvement. The authors included items 4-6 in this domain 
which focuses on if the guideline was developed by appropriate stakeholders and if it represents 
the intended users’ views pertaining to the recommendations. The developer(s) should include 
professionals that are relevant to the clinical problem. The preferences of the target population 
should be considered during the development of the CPG. The target users or providers should 
be clearly labeled (Brouwers et al., 2010). 
Domain 3. Rigor of development. The authors included items 7-14 in this domain which 
pertains to the process used to gather and synthesize current evidence and methods to formulate 
recommendations. It should be relevant that a systematic method was used for searching the 
current evidence based recommendations. The authors should clearly identify criteria for 
evidence selection, strengths and limitations, methods of formulation, externally reviewed by 
experts, and a procedure for updating the CPG as needed (Brouwers et al., 2010). 
Domain 4. Clarity of presentation. The authors included items 15-17 in this domain 
which relates to the language, structure, and format of the CPG. The guidelines should provide 
clear and unambiguous recommendations. The CPG should be well organized and easy to follow 
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process. Any different options for management, such as drug dosing, should be clearly labeled 
(Brouwers et al., 2010). 
Domain 5. Applicability. The authors included items 18-21 in this domain that relates to 
perceived barriers and facilitators to implementation, strategies to increase uptake by providers, 
and resource implications needed for application. There should be an inclusion of advice on how 
the guidelines can be implemented into practice and overcome perceived barriers. Educational 
presentation will be included to provide assistance. The CPG should also present criteria for 
monitoring the outcomes after implementation (Brouwers et al., 2010). 
Domain 6. Editorial independence. The authors included items 22-23 in this domain 
which is concerned with biases associated with the formulation of recommendations and 
competing interests. There should be no concern pertaining to funding bodies that have influence 
the content provided in the CPG. Any competing interests of CPG development should be clearly 
discussed and recorded (Brouwers et al., 2010). 
Overall Guideline Assessment 
The authors included an overall guideline assessment to identify overall judgements of 
the appraisers. The appraiser is asked first to rate the overall quality of the CPG based upon their 
clinical expertise. The second question identifies if they would recommend this guideline for 
local implementation (Brouwers et al., 2010). 
Process and Data Analysis 
The My AGREE PLUS tool is an electronic version of the AGREE II Instrument which 
allows participants to appraise the practice guideline online. The My AGREE PLUS is freely 
available to the public to complete and track current appraisals. Prior to evaluating the CPG, the 
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appraisers first underwent an AGREE II Overview tutorial, which provided an avatar guided 
overview of the AGREE II Instrument that takes approximately 10 minutes to complete. 
Appraisers were provided a copy of the AGREE II Instrument that provides instructions for 
completing the CPG evaluation. Further, appraisers were recommended to complete an AGREE 
II Practice Exercise to improve the standardization of scoring. Each appraiser signed and dated a 
confirmation of their AGREE II training. Depending upon the length and structure of the CPG, 
the actual CPG evaluation is estimated to take an average of 1.5 hours for each appraiser. Each 
item on the AGREE II tool is rated on a 7-point scale, 1 being strongly disagree and 7 being 
strongly agree. The final product from the assessment tool provided combined calculated quality 
scores for each domain that helped determine the recommended use of the CPG (Brouwers et al., 
2010). The anesthesia consultant and PI determined that a domain score of 70% or greater should 
be indicative of a high quality domain. The overall scoring of each domain identifies the CPG’s 
overall quality.  
The CPG was evaluated by four (n=4) independent appraisers to increase its’ reliability 
(Brouwers et al., 2010). Each appraiser was provided access to the AGREE II Overview Tutorial 
and AGREE II Practice Exercise to improve the standardization of scoring. The appraisers also 
received the CPG via email as a PDF file. Further, the appraisers were provided instructions on 
how to create an account on My AGREE PLUS and navigate the website. All information was 
provided by September 17, 2018. The PI coordinated the group appraisal through the My 
AGREE PLUS electronic tool, and the group name was titled “DNP Project: Sugammadex 
Clinical Practice Guideline.” The appraisers were allotted two weeks to assess the CPG and 
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provide valuable insight to its quality. All four appraisals were completed and results compiled 
on September 30, 2018. 
Ethical Considerations 
This DNP project did not include patient participants or vulnerable populations. The 
University of Arizona Institutional Review Board determined this project was not considered 
human research (Appendix F). In regards for the principle of respect for persons, all participants 
were provided disclose information via email and signed an Appraiser Training Confirmation 
form (Appendix I). The email included a full disclosure to the nature and purpose of the project. 
Pertaining to the beneficence principle, this project focused on updating the current standard of 
practice to include the safest delivery of anesthesia. Justice principle was accomplished through 
impartial and volunteer participation.  
RESULTS 
The AGREE II results provide each appraisers’ score per item, inputted comments per 
item, cumulative domain scores as percentages, overall assessment scores, and if the appraiser 
would recommend the CPG (Brouwers et al., 2010). The quantitative results provided by the 
AGREE II Instrument can be found in Appendix E. The scores were further uploaded into an 
organized table format (Table 2).  
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TABLE 2. Seven-point AGREE II score calculator. 
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TABLE 2 – Continued 
Seven-Point AGREE II Score Calculator 
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The combined, calculated domain scores for each of the six domains were 100%, 94%, 
97%, 97%, 99%, and 98% respectively. The six domain scores are independent of each other and 
are calculated separately. Each domain score achieved the 70% quality threshold that was 
predetermined for a high quality domain (Brouwers et al., 2010). The overall assessment of the 
CPG’s quality received a combined score of 96%. Each appraiser (N=4) recommended the 
guideline for clinical use without any modifications.  
One of the advantages with using the My AGREE PLUS electronic tool is that it provides 
comments from the appraiser. The comments enhance clarity to the quantitative scores, however 
they are not considered separate results. The comments included in the AGREE II Instrument are 
not deemed qualitative measures but are only utilized by the appraiser to clarify their numerical 
scoring. Leaving a comment after assessing an item is strictly optional, in which Appraiser 3 and 
Appraiser 4 did not include comments in their evaluation process. Further, there were no 
comments recorded for Domain 4, Clarity of Presentation, or Domain 6, Editorial Independence.  
Comments were recorded for Domain 1, Scope and Purpose, which included items 1 
through 3. Pertaining to item 1, Appraiser 2 vocalized that the cost of glycopyrrolate and 
neostigmine was similar to cost of sugammadex at their institution. Pertaining to item 3, 
Appraiser 2 determined that the target population was “well described.”  
Comments were recorded for Domain 2, Stakeholder Involvement, which included items 
4 through 6. Pertaining to item 4, Appraiser 1 highlighted the potential benefit of including a 
pharmacist for development of the guideline. Pertaining to item 6, Appraiser 1 and Appraiser 2 
thought the target users of the guideline could be expanded to include postoperative care unit 
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nurses, critical care medicine physicians, and critical care nurses. Further, Appraiser 2 did not 
appreciate the term Physician Anesthesiologist in identifying the target users of this guideline.  
Comments were recorded for Domain 3, Rigour of Development, which included items 7 
through 14. Pertaining to item 9, Appraiser 2 expressed concern with the lack of a definition to 
the term recurarization, in which potential users of the guideline could be confused to its 
meaning. Pertaining to item 12, Appraiser 2 deemed the key recommendations as “current and 
well-documented”. Pertaining to item 14, Appraiser 2 expressed concern that 5 years for 
updating the guideline may be too long.  
Comments were recorded for Domain 5, Applicability, which included items 18 through 
21. Pertaining to item 19, Appraiser 1 determined that the algorithm was “very well made, 
concise, and easy to follow” and Appraiser 2 stated that they “loved the algorithm… very 
clear/easily utilized”.  
DISCUSSION 
The results provided through the AGREE II Instrument have deemed this CPG as high 
quality. Each domain score achieved and surpassed the predetermined quality threshold of 70%. 
All the appraisers of the CPG recommended its guideline and key components for clinical use 
without modifications. The key recommendations identified clinical scenarios that deemed the 
necessity of sugammadex administration; including 1) as a rescue therapy in the rare but life-
threatening “cannot-ventilate, cannot-intubate” situation, 2) for residual, moderate, or deep 
neuromuscular blockade, in which the patient would either be at risk for inadequate reversal with 
standard reversal agents or any further administration of standard reversal agents is 
contraindicated, and 3) to ensure complete reversal for patients with significant comorbidities 
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that are at risk for postoperative complications. Including patients with neuromuscular disease, 
respiratory disease, cardiovascular disease, hepatic dysfunction, advanced age, morbid obesity, 
and obstructive sleep apnea. The overall quality of the CPG received a combined score of 96%, 
with only one appraiser not rating a perfect score. 
Given the scores and appraiser comments, Domain 2, Stakeholder Involvement, proved to 
be the weakest domain. The overall score of 94% was the lowest combined domain score. It still 
achieved the quality threshold, however there were a couple factors that could have improved its 
overall score. There was a concern identified that a pharmacist was not included in the CPG 
development team. The inclusion of a pharmacist stakeholder in the development process would 
have enhanced a significant facilitator for the guideline’s overall implementation. As well, there 
were concerns to the predetermined target users of the guideline. It could be beneficial to include 
intraoperative and postoperative care nurses whom provided valuable assessments of the 
patient’s condition. However, the inclusion of critical care medicine physicians and critical care 
nurses would not be indicated for this CPG due to its focus on the perioperative phase.  
Dissemination Plan 
The goal of the CPG is to translate the best evidence into the best practice. Key leaders at 
the designated facility were sought out during the guideline development process and after the 
AGREE II evaluation to disseminate the results. The key leaders included the Medical Director 
of Anesthesia and the Chief CRNA; in which they both provide valuable influence that can 
change the current practice at the site and have significant relationships in place to overcome 
organizational barriers.  
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An oral presentation was provided to the leaders pertaining to the CPG and the AGREE 
II results, in which they both deemed the guideline as high quality. After the presentation, a 
questionnaire was utilized to evaluate the overall intent to change and implement into practice 
(Appendix G). This questionnaire was separate from the AGREE II results above, and was 
developed to determine intent to change. They both identified that the rationale for developing a 
CPG for the use of sugammadex was clear and there is a significant need for it at their 
institution. They both determined that the key recommendations were clear, suitable for their 
patient population, provided more benefit than harm, and were interpreted correctly with current 
literature. Further, they agreed with implementing the key recommendations as stated without 
modifications. Both leaders denied that the CPG would be difficult to apply, and agreed that the 
majority of their colleagues would support the change. They both identified that the key 
recommendations reflected a more effective approach for improving patient outcomes than 
currently used practices. When asked if the CPG should be approved as a practice guideline, both 
leaders selected “strongly agreed”. When asked if they would use the CPG in their own practice 
if it had previously been approved as a practice guideline, both leaders selected “strongly agree”. 
When asked if they would apply the recommendation to their own patients if it had previously 
been approved as a practice guideline, both leaders selected “strongly agree”. Both key leaders 
expressed their intent to change and implement this CPG into practice.  
The only organizational barrier that currently stands is pharmacy’s previous resistance to 
purchasing sugammadex and including it within the facility’s pharmaceutical formulary. The 
pharmacist whom controls the pharmacy budget has stated their concerns that the reversal per 
patient is more expensive with sugammadex compared to the neostigmine/glycopyrrolate 
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mixture. Both leaders have developed a respectable relationship with pharmacy and are planning 
a meeting to reevaluate the decision to incorporate sugammadex. Both leaders selected “neither 
agree or disagree” when asked if the CPG was too expensive to apply, due to their perspective 
that it could significantly reduce postoperative complications, time in the operating room, time in 
the PACU, and costly intensive care admissions.  
Overall, the anesthesia leaders were able to get sugammadex approved and now on 
formulary through collaboration with pharmacy. They both deemed that the CPG is of high 
quality and expressed their intent to integrate it into their anesthesia practice. The results were 
disseminated to these anesthesia leaders as they comprehend the current facility’s barriers and 
facilitators and have significant influence on pertinent organizational decisions.  
The results will be further presented during the AZANA Annual Sun & Fun Conference 
in March, 2019 and the NMANA Nurse Anesthesia Conference in September, 2019. This will 
include a presentation of the CPG and results to anesthesia providers around the state. 
Strengths, Weaknesses and Limitations 
This DNP project has had many potential strengths that supported its development 
process and acceptance by key stakeholders. Most importantly, the literature that was used to 
support the effectiveness of sugammadex was of high level evidence that supported strong 
recommendations. The synthesis of evidence and majority studies used in this DNP project 
included random controlled trials, systematic reviews, and meta-analyses. These study designs 
are considered of the highest level of evidence (Burns, Rohrich, & Chung, 2011). Further, the 
use of sugammadex is gaining much momentum in current anesthesia practice which enabled the 
PI to find enthusiastic volunteers. The AGREE II Instrument used in this DNP project is 
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identified as one of the most credible assessment tools for appraising CPGs, in that it has been 
cited in well over 600-hundred different publications (Brouwers et al., 2010). The PI was able to 
recruit the ideal amount of appraisers for this DNP project, in that the AGREE II team 
encourages at least two but preferably four participants (Brouwers et al., 2010). The four 
volunteer appraisers are anesthesia experts whom are currently using sugammadex in practice 
and were not biased, full-time employees at the designated facility. Lastly, the PI of this DNP 
project was able to implore the strong rapport established with key anesthesia leaders at the 
facility, in which they have expressed their strong intent to change and implement.  
The fact that the CPG was developed by a single PI whom had limited influence at the 
designated facility was the most recognized weakness to this DNP project. As identified in the 
AGREE II results, the lowest scoring aspect in the assessment tool was the stakeholder 
involvement. The domain entailed the item of including all relevant professional groups in the 
guideline development group, in which the inclusion of a pharmacist could have enhanced the 
overall quality of the CPG. However, the appraiser that highlighted the need to incorporate a 
pharmacist determined that it was also “highly appropriate” to seek out expert anesthesia 
providers for the development phase.  
One of the limitations to the use of the AGREE II Instrument is that the assessment tool 
cannot guarantee appropriate or improved patient outcomes based solely on rigor of development 
(Brouwers et al., 2010). Simply using the AGREE II Instrument does not ensure that the 
appraised CPG is flawless, however it does increase the probability of producing high quality 
recommendations. Another limitation is that the DNP project was developed for a single 
institution, and may have limited representativeness. Some healthcare organizations may have no 
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barriers resisting the use of sugammadex in anesthesia practice, and a CPG that identifies which 
clinical scenarios are appropriate for sugammadex is unwarranted.  
Incorporation of DNP Essentials 
The eight DNP essentials were incorporated in this DNP project to see it to fruition.  
 DNP I: Application of scientific underpinnings to practice was clearly completed through 
the inclusion of LCT and the KTA Framework in the theoretical section of this DNP 
project.  
 DNP II: Application of organizational and systems leadership for quality improvement 
and systems thinking was accomplished through engagement of key leaders to help 
facilitate implementation.  
 DNP III: Application of clinical scholarship and analytical methods of evidence-based 
practice was the bases for the entire methodology of this DNP project in that it aimed to 
progress current evidence into current practice by developing a CPG.  
 DNP IV: Application of information systems/technology and patient care technology for 
the improvement and transformation of heath care was clearly completed with utilization 
of the My AGREE PLUS electronic tool which allows appraisers to assess CPGs online 
and provided combined quality results.  
 DNP V: Application of healthcare policy for advocacy in healthcare was applied by 
adapting the CPG for regulated use of sugammadex due to the current economic status of 
the healthcare organization.  
 DNP VI: Application of interprofessional collaboration for improving patient and 
population health outcomes was completed by engaging CRNAs and physician 
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anesthesiologists in this DNP project, as well as addressing the need to reach out to 
pharmacy stakeholders.  
 DNP VII: Application of clinical prevention and population health for improving the 
nation’s health had limited involvement in this DNP project, however the overall aim was 
to reduce postoperative patient risks and improve the perioperative population’s health 
outcomes.  
 DNP VIII: Application of advanced practice competencies was represented with the PI’s 
advanced knowledge pertaining to the neuromuscular junction physiology, advanced 
pharmacotherapeutics, and background knowledge to the issue of recurarization. The 
eight DNP essentials were clearly recognized throughout this DNP project. 
The eight DNP essentials were clearly recognized throughout this DNP project. 
Conclusion 
The use of sugammadex is revolutionizing how anesthesia providers are reversing 
neuromuscular blockade. Sugammadex implementation compared to currently used practices has 
the capability to reduce postoperative patient risks and complications. A current and evidence-
based CPG was developed with the input from key stakeholders. The presented CPG in this 
project will provide guidance to anesthesia providers on the appropriate use of sugammadex, and 
will help propel change forward for the designated facility. DNP prepared APRNs are in place to 
make significant changes in healthcare and ensure that evidence-based CPGs correlate to best 
practices. This DNP project was able to develop a CPG that produced quality-driven, evidence-
based recommendations that promotes applicability and implores intent to change. 
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Domain 1: Scope and Practice 
1. The overall objective (s) of the guideline(s) is specifically described. 
2. The health question (s) covered by the guideline is (are) specifically described.  
3. The population to whom the guideline is meant to apply is specifically described.  
Domain 2: Stakeholder Involvement 
4. The guideline development group includes individuals from all relevant professional groups.  
5. The views and preferences of the target population have been sought.  
6. The target users of the guideline are clearly defined.  
Domain 3: Rigour of Development 
7. Systematic methods were used to search for evidence.  
8. The criteria for selecting the evidence are clearly described.  
9. The strengths and limitations of the body of evidence are clearly described.  
10. The methods for formulating the recommendations are clearly described. 
11. The health benefits, side effects, and risks have been considered in formulating the recommendations.  
12. There is an explicit link between the recommendations and the supporting evidence.  
13. The guideline has been externally reviewed by experts prior to its publication.  
14. A procedure for updating the guideline is provided.  
Domain 4: Clarity of Presentation 
15. The recommendations are specific and unambiguous.  
16. The different options for management of the condition or health issue are clearly presented.  
17. Key recommendations are easily identifiable.  
Domain 5: Applicability  
18. The guideline describes facilitators and barriers to its application.  
19. The guideline provides advice and/or tools on how the recommendation can be put into practice.  
20. The potential resource implications of applying the recommendation have been considered.  
21. The guideline presents monitoring and/or auditing criteria.  
Domain 6: Editorial Independence 
22. The views of the funding body have not influenced the content of the guideline.  
23. Competing interests of guideline development group members have been recorded and addressed.  
Overall Guideline Assessment 
1. Rate the overall quality of the guideline.  
2. I would recommend this guideline for use.  
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AGREE II Score Sheet 
 
Domain Item 
AGREE II Rating 
1 
Strongly 
Disagree 
2 3 4 5 6 
7 
Strongly 
Agree 
Scope and 
purpose 
 
1. The overall objective(s) of the guideline is (are) specifically described.        
2. The health question(s) covered by the guideline is (are) specifically described.        
3. The population (patients, public, etc.) to whom the guideline is meant to apply is 
specifically described. 
       
Stakeholder 
involvement 
4. The guideline development group includes individuals from all the relevant 
professional groups. 
       
5. The views and preferences of the target population (patients, public, etc.) have 
been sought. 
       
6. The target users of the guideline are clearly defined.        
Rigor of 
development 
7. Systematic methods were used to search for evidence.        
8. The criteria for selecting the evidence are clearly described.        
9. The strengths and limitations of the body of evidence are clearly described.        
10. The methods for formulating the recommendations are clearly described.        
11. The health benefits, side effects and risks have been considered in formulating 
the recommendations. 
       
12. There is an explicit link between the recommendations and the supporting 
evidence. 
       
13. The guideline has been externally reviewed by experts prior to its publication.        
14. A procedure for updating the guideline is provided.        
Clarity of 
presentation 
15. The recommendations are specific and unambiguous.        
16. The different options for management of the condition or health issue are 
clearly presented. 
       
17. Key recommendations are easily identifiable.        
Applicability 18. The guideline describes facilitators and barriers to its application.        
19. The guideline provides advice and/or tools on how the recommendations can 
be put into practice. 
       
20. The potential resource implications of applying the recommendations have 
been considered. 
       
21. The guideline presents monitoring and/ or auditing criteria.        
Editorial 
independence 
22. The views of the funding body have not influenced the content of the guideline.        
23. Competing interests of guideline development group members have been 
recorded and addressed. 
       
Overall 
Guideline 
Assessment 
1. Rate the overall quality of this guideline. 
 
1  
Lowest 
possible 
quality 
2 3 4 5 6 
7 
Highest 
possible 
quality 
Overall 
Guideline 
Assessment 
2. I would recommend this guideline for use. Yes Yes, with modifications No 
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Perioperative Administration of Sugammadex: A Clinical Practice Guideline 
 
Report Date: September 15, 2018 
 
Scope and Purpose 
 
Objectives 
 
This guideline provides certified nurse anesthetists and physician anesthesiologists evidence-
based methods for reversal of rocuronium or vecuronium induced neuromuscular blockade with 
the administration of sugammadex with the goal of optimizing patient safety. Sugammadex is a 
more expensive reversal agent compared to conventional anticholinesterase agents and has the 
potential to increase drug expenditure. This guideline provides evidence-based clinical 
indications for the use of sugammadex, as it has been found to provide a faster and more efficient 
reversal. Secondary objectives include introducing evidence-based key recommendations for 
diagnostic values of level of blockade, prevention of postoperative complications, and treatment 
for high risk patient populations.  
 
Questions 
 
What are the most appropriate clinical indications for the use of sugammadex in the 
perioperative phase? What patient populations are at risk for postoperative complications related 
to residual paralysis?  
 
Target Population 
 
This guideline is intended for adult patient populations, age 18 years old or greater, male and 
female, who received either rocuronium or vecuronium intraoperatively. Patients excluded from 
this guideline include those aged 17 years or younger, have severe renal impairment, have a 
known sensitivity to sugammadex, or received a different neuromuscular blocking agent.  
 
Intended Users 
 
Physician Anesthesiologists 
 
Certified Registered Nurse Anesthetists 
 
Student Registered Nurse Anesthetists 
 
Pharmacists  
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Key Recommendations 
 
Sugammadex demonstrates the capability of reversing neuromuscular blockade more timely and 
effectively (2,3,7,10). It has shown clinical advantages for patients with preexisting comorbidities 
and reducing risks of postoperative respiratory, cardiac, and recurarization complications (2, 5, 7, 
10). However, due to current cost implications and limited evidence supporting cost effectiveness, 
the use of sugammadex should be restricted for specific situations only.  
 
Sugammadex reversal of rocuronium or vecuronium induced neuromuscular blockade in the 
following indications:  
 
1. As a rescue therapy in the rare but life-threatening “cannot-ventilate, cannot-intubate” 
situation (4).  
 
Aggregate Evidence Quality Grade A 
Benefits Effective reversal of profound neuromuscular blockade 
within 3 minutes after sugammadex administration. All 
other standard reversal agents are contraindicated with 
the depth of blockade. Negates significant risks of 
hypoventilation, hypoxemia, and respiratory arrest 
related to a “cannot-ventilate, cannot-intubate” 
emergency situation. 
Risk, Harm, Costs Risk of adverse effects of pharmacological 
intervention; cost for high dose sugammadex.  
Benefits-Harms Assessment  Preponderance of benefit 
Level of Evidence 1A 
Descriptor Strong Recommendation 
 
2. For residual, moderate, or deep neuromuscular blockade, in which the patient would 
either be at risk for inadequate reversal with standard reversal agents or any further 
administration of standard reversal agents is contraindicated (2,3,7).  
 
Aggregate Evidence Quality Grade A 
Benefits Effective reversal of neuromuscular blockade at any 
depth within 3 minutes after sugammadex 
administration. Reduces the risk of postoperative 
recurarization and correlated postoperative 
complications. Current standard reversal agents are 
contraindicated for deep neuromuscular blockade or 
after maximum doses already administrated with 
residual paralysis.  
Risk, Harm, Costs Risk of adverse effects of pharmacological 
intervention; cost for sugammadex.  
Benefits-Harms Assessment  Preponderance of benefit 
Level of Evidence 1A 
Descriptor Strong Recommendation 
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3. To ensure complete reversal for patients with significant comorbidities that are at risk 
for postoperative complications. Including patients with neuromuscular disease (11), 
respiratory disease (2,5), cardiovascular disease (2), hepatic dysfunction (1), advanced age 
(8), morbid obesity (5,6), and obstructive sleep apnea (6,10).  
 
Aggregate Evidence Quality Grade A 
Benefits Effective reversal of neuromuscular blockade within 3 
minutes after sugammadex administration. Ensure 
unequivocal reversal of paralysis for high risk patient 
populations. Negates significant risks of respiratory, 
cardiovascular, or global adverse events 
Risk, Harm, Costs Risk of adverse effects of pharmacological 
intervention; cost for sugammadex.  
Benefits-Harms Assessment  Preponderance of benefit 
Level of Evidence 1B 
Descriptor Strong Recommendation 
 
Supporting Evidence 
 
Published cost-analysis evaluations reveal that there may be some significant resource savings 
due to reduced postoperative adverse events and less time stayed in the operating rooms and 
postoperative care units, however there is limited applicability due to changes in pharmaceutical 
costs and variety of surgical specialties (1-11).  
 
1. Abdulatif, M., Lotfy, M., Mousa, M., Afifi, M., & Yassen, K. (2018). Sugammadex 
antagonism of rocuronium-induced neuromuscular blockade in patients with liver 
cirrhosis undergoing liver resection: a randomized controlled study. Minerva 
Anestesiologica. 
2. Carron, M., Zarantonello, F., Tellaroli, P., & Ori, C. (2016). Efficacy and safety of 
sugammadex compared to neostigmine for reversal of neuromuscular blockade: a meta-
analysis of randomized controlled trials. Journal of Clinical Anesthesia, 35, 1-12. 
3. Carron, M., Zarantonello, F., Lazzarotto, N., Tellaroli, P., & Ori, C. (2017). Role of 
sugammadex in accelerating postoperative discharge: A meta-analysis. Journal of 
Clinical Anesthesia, 38-44. 
4. Chambers, D., Paulden, M., Paton, F., Heirs, M., Duffy, S., Hunter, J., Sculpher, M., & 
Woolacott, N. (2010). Sugammadex for reversal of neuromuscular block after rapid 
sequence intubation: a systematic review and economic assessment. British Journal of 
Anaesthesia, 105(5), 568-575. 
5. Evron, S., Abelansky, Y., Ezri, T., & Izakson, A. (2017). Respiratory events with 
sugammadex vs. neostigmine following laparoscopic sleeve gastrectomy: a prospective 
pilot study assessing neuromuscular reversal strategies. Romanian Journal of Anaesthesia 
and Intensive Care, 24, 111-114.  
6. Hafeez, K., Tuteja, A., Singh, M., Wong, D., Nagappa, M., Chung, F., & Wong, J. (2018). 
Postoperative complications with neuromuscular blocking drugs and/or reversal agents in 
obstructive sleep apnea patients: a systematic review. BMC Anesthesiology, 18(1). 
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7. Hristovska, A., Duch, P., Allingstrup, M., & Afshari, A. (2017). The comparative efficacy 
and safety of sugammadex and neostigmine in reversing neuromuscular blockade in 
adults. A Cochrane systematic review with meta-analysis and trial sequential analysis. 
Anaethesia. 
8. McDonagh, D., Benedict, P., Kovac, A., Drover, D., Brister, N., Morte, J., & Monk, T. 
(2011). Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of 
rocuronium-induced neuromuscular blockade in elderly patients. The Journal of the 
American Society of Anesthesiologists, 114(2), 318-329. 
9. Robertis, E., Marinosci, G., Romano, G., Piazza, O., Iannuzzi, M., Cirillo, F., et al. (2016). 
The use of sugammadex for bariatric surgery: analysis of recovery time from 
neuromuscular blockade and possible economic impact. ClinicoEconomics and Outcomes 
Research, 317-322. 
10. Unal, D., Baran, I., Mutlu, M., Ural, G., Akkaya, T., & Ozlu, O. (2015). Comparison of 
Sugammadex versus Neostigmine Costs and Respiratory Complications in Patients with 
Obstructive Sleep Apnoea. Turkish Journal of Anaesthesiology and Reanimation, 387-
395. 
11. Vymazal, T., Krecmerova, M., Bicek, V., & Lishke, R. (2015). Feasibility of full and 
rapid neuromuscular blockade recovery with sugammadex in myasthenia gravis patients 
undergoing surgery - a series of 117 cases. Therapeutics and Clinical Risk Management, 
1593-1596. 
 
Sugammadex Prescribing Information 
Monitoring 
Criteria 
Intraoperative monitoring: document the neuromuscular blocking agent used (rocuronium 
or vecuronium) and assessment with peripheral nerve stimulator prior to sugammadex 
administration.  
 Profound blockade: absent train-of-four and post tetanic count  
 Deep blockade: absent train-of-four with 1 to 2 post-tetanic counts 
 Standard blockade: train-of-four greater than 2 twitches  
Postoperative monitoring: document reversal agent used and dose. Continue facility 
standard monitoring, and appropriate measures for the specific comorbidities and surgical 
procedure.  
 
Dose Profound reversal (emergency): 16 mg/kg 
Deep reversal: 4 mg/kg 
Standard reversal: 2 mg/kg 
Administration Give as a single bolus injection, within 10 seconds, into an existing intravenous line.  
Precautions Not recommended for use in pediatric patients or patients with severe renal disease. Patient 
with hypersensitivity to sugammadex is at risk of anaphylaxis, continue to monitor for an 
appropriate period of time post administration. Risk of marked bradycardia within 3 min of 
administration, monitor for hemodynamic changes and treat with anticholinergic is severe 
bradycardia is observed.  
Merck. (2015). Sugammadex Full Prescribing Information. New Jersey: Merck Sharp & Dohme Corp.  
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Implementation Algorithm 
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Methods 
 
Search Methods and Criteria Selection 
 
Scientific evidence was utilized in the development of this guideline. Search of electronic 
databases included PubMED, CINAHL, and Cochrane Library. Key search terms were included 
sugammadex, neostigmine, neuromuscular blockade, obesity, geriatrics, liver disease, renal 
disease, sleep apnea, rapid sequence induction, safety, and efficacy. Criteria for inclusion 
consisted of recent publication after 2010, peer-reviewed, full text availability, and English 
language. Study designs considered included meta-analyses, systematic reviews, and random 
controlled trials.  
 
Strength of Evidence 
 
The level of evidence was first evaluated and considered when grading each recommendation. 
The figures below were utilized for the determination of strength of evidence. 
 
Level Type of evidence 
1A Systematic review (with homogeneity) of RCTs  
1B Individual RCT (with narrow confidence interval)  
1C All or none study  
2A Systematic review (with homogeneity) of cohort studies 
2B Individual cohort study (including low quality RCT) 
2C “Outcomes” research; Ecological studies 
3A Systematic review (with homogeneity) of case-control studies 
3B Individual case-control studies 
4 Case series (and poor quality cohort and case-control studies) 
5 Expert opinion; case report or clinical example; or evidence based on physiology 
Burns, P., Rohrich, R., & Chung, K. (2011). The Levels of Evidence and their role in Evidence-Based Medicine. Plastic 
and Reconstructive Surgery, 128(1), 305-310.  
 
Grade Descriptor Qualifying Evidence Implications for Practice 
A Strong 
recommendation 
Level I evidence or 
consistent findings from 
multiple studies of levels 
II, III, or IV 
Clinicians should follow strong recommendation unless 
clear or compelling rationale for an alternative approach 
is present 
B Recommendation Levels II, III, or IV 
evidence and findings are 
generally consistent  
Generally, clinicians should follow a recommendation 
but should remain alert to new information and sensitive 
to patient preferences 
C Option Levels II, III, or IV 
evidence, but findings are 
inconsistent 
Clinicians should be flexible in their decision-making 
regarding appropriate practice, although they may set 
bounds on alternatives; patient preference should have a 
substantial influencing role 
D Option Level V evidence; little or 
no systematic empirical 
evidence 
Clinicians should consider all options in their decision 
making and be alert to new published evidence that 
clarifies the balance of benefit versus harm; patient 
preference should have a substantial influencing role 
Burns, P., Rohrich, R., & Chung, K. (2011). The Levels of Evidence and their role in Evidence-Based Medicine. Plastic 
and Reconstructive Surgery, 128(1), 305-310. 
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External Review and Updating Procedure 
 
External peer review was completed by an anesthesia provider not associated with the guideline 
development or application. Purpose is to determine quality and clarity, gather feedback, and 
disseminate results. External peer review was completed by Sarah Torabi, DNP, CRNA. The 
guideline will undergo internal peer review every five years for newly published literature to 
support or dissuade current recommendations.  
 
Stakeholder Involvement 
The guideline and algorithm was developed by Timothy Markle, SRNA from the 
University of Arizona. The intended goal was to encourage and implement sugammadex 
availability at a healthcare facility in the Phoenix Metropolitan area. Key anesthesia personnel 
provided valuable clinical and institutional insight for this guideline development. The 
preference of the target population was considered with the overall goal to increase patient safety 
in the postoperative phase. 
 
Facilitators/Barriers to Implementation 
This guideline was developed with the input and feedback from key stakeholders at Mountain 
Vista Medical Center. All required resources, such as peripheral nerve stimulator, are currently 
available to the anesthesia personnel. Cost implications to pharmaceutical budget will be the 
single most pertinent barrier of implementation. 
 
Funding/Conflict of Interest 
This guideline was developed as the project of a Doctor of Nursing Practice student. There was 
no funding required for this project. All work produced by the author is editorially independent 
and free from competing interests.  
  
Disclaimer 
Great effort has been provided in the preperation of this guideline. Nonetheless, any person 
intending to implement or apply these evidence-based recommendations is expected to use 
indepenedint clinical judgement in context to each disticnt clinical circumstance or seek out 
supervision from a qualified clinician. 
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APPENDIX F: 
THE UNIVERSITY OF ARIZONA INSTITUTIONAL REVIEW BOARD (IRB) 
DETERMINATION OF HUMAN RESEARCH FORM 
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DISSEMINATION RESULTS 
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V 2013-01 
 
Anesthesia Physicians of Arizona 
1301 South Crimson Road 
Mesa, AZ 85209 
 
June 9, 2018 
 
University of Arizona Institutional Review Board 
c/o Office of Human Subjects 
1618 E Helen St 
Tucson, AZ  85721 
 
Please note that Mr. Timothy Markle, UA Doctor of Nursing Practice student, has permission of 
Anesthesia Physicians of Arizona to conduct an evidence-based project for his project, “Development of a 
Clinical Practice Guideline for the Use of Sugammadex.”   
 
Mr. Markle will develop a clinical practice guideline with the input of a CRNA from our anesthesia 
group. The CRNA will provide expert opinion and valuable organizational insight from Mountain Vista 
Medical Center. This will include an interview conducted off site as agreed upon from both parties. Mr. 
Markle’s activities will be completed by December 31, 2018. 
 
Mr. Markle has agreed to provide the developed clinical practice guideline and evaluation results upon 
completion. He has further agreed to present the results to the providers as per organizational 
determination. 
 
If there are any questions, please contact my office. 
 
Signed, 
 
 
Dr. Ned Sciortino 
Medical Director of Anesthesia 
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APPRAISER DISCLOSURE EMAIL 
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Dear Appraiser,  
 
You have been selected to contribute significant insight and expertise for my DNP project, 
“Development of a Clinical Practice Guideline for the Use of Sugammadex”. 
 
The purpose of this project is to identify the current evidence-based recommendations for the 
reversal of neuromuscular blockade with Sugammadex and develop a high quality clinical 
practice guideline at the organizational level.  
 
If you choose to take part in this project, you will be asked to appraise the clinical practice 
guideline for quality and applicability. It will take approximately 10 minutes to complete an 
AGREE II Overview tutorial and 90 minutes to evaluate the developed clinical practice 
guideline. There are no foreseeable risks associated with participating in this project and you will 
receive no immediate benefit from your participation. Evaluation responses are anonymous.  
 
If you choose to participate in the project, participation is voluntary, refusal to participate will 
involve no penalty or loss of benefits to which you are otherwise entitled. You may withdraw at 
any time from the project. In addition, you may skip any question that you choose not to answer. 
By participating, you do not give up any personal legal rights you may have as a participant in 
this project. 
 
For questions, concerns, or complaints about the project, you may call Timothy Markle BSN, 
RN, SRNA at (602) 568-3236 or tsmarkle@email.arizona.edu. 
 
Thank you for volunteering and for the time that you have sacrificed.  
 
Sincerely,  
 
Timothy Markle BSN, RN, SRNA 
University of Arizona 
tsmarkle@email.arizona.edu 
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